Clodronate in the management of different musculoskeletal conditions by Frediani, Bruno et al.
300 Minerva Medica august 2018 
R E V I E W
clodronate in the management 
of different musculoskeletal conditions
Bruno Frediani 1 *, andrea GiUSTi 2, Gerolamo BiancHi 3, Luca daLLe carBOnare 4, 
nazzarena MaLavOLTa 5, Luca canTarini 1, Gianantonio SaviOLa 6, Luigi MOLFeTTa 7
1department of rheumatology, Osteoporosis and Osteoarticular instrumental diagnosis center, University of 
Siena, Siena, italy; 2department of Ortho-Geriatrics, rehabilitation and Stabilization, Frailty area, Bone clinic, 
Galliera Hospital, Genoa, italy; 3division of rheumatology, department of Locomotor System, aSL003, Genoa, 
italy; 4department of Medicine, University of verona and azienda Ospedaliera Universitaria integrata verona, 
verona, italy; 5division of rheumatology, department of cardiac Thoracic and vascular disease, University of 
Bologna, Bologna, italy; 6Unit of rheumatology and rehabilitation, Salvatore Maugeri Foundation irccS, castel 
Goffredo, Mantua, italy; 7division of Orthopedics and Traumatology, School of Medical and Pharmaceutical 
Science, dinOGMi department, Section of Orthopedic rehabilitation, University of Genoa, Genoa, italy
*corresponding author: Bruno Frediani, rheumatology department, Osteoporosis and Osteoarticular instrumental diagnosis center, 
University of Siena, Siena, italy. e-mail: fredianibruno60@gmail.com
a B S T r a c T
inTrOdUcTiOn: clodronic acid is a non-nitrogen-containing bisphosphonate largely used from some decades in the 
prevention and treatment of postmenopausal and secondary osteoporosis. in addition to antiresorptive activity, clodronate 
has shown anti-inflammatory and analgesic properties, and modulatory effects on bone and cartilage metabolism.
evidence acQUiSiTiOn: a literature review has been conducted to characterize the mechanism of action of clo-
dronate and to retrieve available evidence about the use of clodronate in primary and secondary osteoporosis, and its 
potential role in other musculoskeletal conditions and orthopedic surgery.
EVIDENCE SYNTHESIS: The efficacy and safety of the available clodronate formulations (oral, intravenous and in-
tramuscular) in the prevention and treatment of postmenopausal and secondary osteoporosis, including corticosteroid-
induced osteoporosis and bone mass loss secondary to endocrine, gastrointestinal and neoplastic diseases, have been 
demonstrated in a variety of clinical trials. The analgesic, anti-inflammatory, bone- and chondro-modulating properties 
of clodronate have allowed to expand its use in other musculoskeletal conditions to those currently approved. clodronate 
has proven to be beneficial in the treatment of osteoarthritis of the knee and of the hand, in the management of complex 
regional pain syndrome, and in the peri- and postoperative phase in subjects undergoing arthroplasty.
cOncLUSiOnS: The analysis of the available literature has shown that clodronate has relevant musculoskeletal effects 
beyond the antiresorptive activity. Further research is needed to better position clodronate therapy in the management of 
these conditions and to define the optimal formulation and dose regimen in any of the tested new indications.
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Introduction
Bisphosphonates (BPs) are the most common-ly used drugs in the treatment of postmeno-
pausal osteoporosis and other metabolic bone 
diseases, such as bone loss induced by hormone 
suppressive therapy or glucocorticoids. although 
the most important biological effect of BPs re-
mains the reduction of bone remodeling through 
the inhibition of osteoclastic activity, there are 
important differences between individual BPs in 
the extra-skeletal immune-modulating and anti-
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inflammatory effects that may expand the use of 
these therapeutic agents in clinical practice.1
clodronate disodium is a non-nitrogen-con-
taining BP (NNBP) that is available in Europe as 
oral, intravenous (i.v.), and intramuscular (i.m.) 
formulations for the treatment of hypercalce-
mia and/or osteolysis of malignancy, multiple 
myeloma, and for the prevention and treatment 
of post-menopausal osteoporosis. The effects of 
clodronate in the current indications are largely 
documented in a variety of clinical trials con-
ducted over more than two decades.2 in recent 
years, there is accumulating evidence that clo-
dronate may be effective in the treatment of other 
conditions, such as bone marrow edema and as-
sociated syndromes, erosive osteoarthritis of the 
hands, rheumatoid arthritis, as well in subjects 
undergoing prosthetic surgery.2, 3 The positive 
biological effects of clodronate in extra-skeletal 
conditions are not only related to its antiresorp-
tive action, but to a more complex interaction 
between its pharmacological properties and the 
underlying pathophysiological mechanisms. 
Furthermore, the development of formulations 
suitable for intermittent dosing regimens has al-
lowed to maintain the efficacy profile of clodro-
nate and to tailor the therapeutic scheme to indi-
vidual patients’ need while improving adherence 
and persistency of treatment.1
This article reviews the recent insights on the 
mechanism of action of clodronate, the available 
literature on its consolidated use in the preven-
tion and treatment of osteoporosis, and its poten-
tial use in other musculoskeletal conditions, in-
cluding patients’ undergoing orthopedic surgery.
Evidence acquisition
The search in literature has been performed with 
no time limitation using PubMed/Medline and 
searching for the term “clodronate” Or “clo-
dronic acid” with no language restriction. all au-
thors read the abstracts of all publications identi-
fied on the electronic databases, excluding only 
those that clearly did not meet the objectives of 
this review. Then, authors read the full-text arti-
cles of the selected publications and a consensus 
was made on those studies to be considered as 
suitable for citation.
The search has also been expanded to evalu-
ate the documentation of the effects of other BPs 
(alendronate, risedronate, ibandronate, zoledro-
nate, pamidronate, neridronate) in other non-ap-
proved indications for clodronate.
Evidence synthesis
Clodronate: mechanism of action
All BPs reduce osteoclast activity. NBPs (alen-
dronate, risedronate, ibandronate, zoledronate, 
pamidronate, neridronate) specifically inhibit 
the enzyme farnesyl diphosphate synthase and 
block the prenylation of guanosine triphosphate-
binding proteins that are essential for osteoclast 
function.4 In contrast, NNBPs (etidronate, clo-
dronate) induce the production of toxic analogs 
of adenosine triphosphate (ATP) that accumulate 
intracellularly in osteoclasts, resulting in induc-
tion of osteoclast apoptosis.5 The antifracture ef-
fect of each BP is dependent on its ability to bind 
rapidly and with high affinity to the bone surface 
and on its antiresorptive potency.
BPs are analogs of inorganic pyrophosphate, 
and are composed of an enzyme-resistant phos-
phorus-carbon-phosphorus (P-C-P) structure 
able to adhere strongly to hydroxyapatite crys-
tals. They have a relatively simple core struc-
ture, and the pharmacologic properties of each 
BP molecule depend on lateral chains, named r1 
and r2. The P-c-P nucleus and r1 lateral chain 
are responsible for anchoring the drug to the 
bone mineral matrix, while r2 has biologic and 
therapeutic actions. The presence of a hydroxyl 
group in R1 markedly increases BPs affinity for 
the bone matrix, while the nitrogen atom in r2 is 
responsible for antiresorptive potency.5
The therapeutic effect of BPs is mediated 
mainly by the inhibition of osteoclastic bone 
resorption, as demonstrated in bone biopsies, 
where fewer numbers of osteoclasts and lower 
bone erosion rates have been observed.4 Once 
embedded on the bone surface, BPs are slowly 
released into the bone matrix where they affect 
osteoclasts by reducing their differentiation, re-
cruitment, and activity. in fact, it is believed that 
BPs are taken up by osteoclasts during bone re-
sorption and, under their influence, osteoclasts 
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mitochondrial membrane potential.10 The subse-
quent decrease is probably due to some secondary 
adverse effects on the mitochondrial energy state. 
appccl2p is a competitive inhibitor with respect 
to aTP, and this metabolite could therefore inter-
fere with several aspects of mitochondrial metabo-
lism connected to respiratory chain, such as pyro-
phosphate translocation into the inner membrane. 
early mitochondrial events in cellular apoptosis 
include dissipation of its membrane potential, in-
creased levels of ca2+, nadPH oxidation, burst 
of reactive oxygen species, increased opening of 
the mitochondrial permeability transition (PT) 
pore, and release of cytochrome c and other pro 
apoptotic factors into the extra-mitochondrial 
space. anT form the PT pore when associated 
with cyclophilin-d in the mitochondrial matrix 
and the non-selective voltage-dependent anion 
channel in the mitochondrial outer membrane. 
cyclosporin a and some anT inhibitors inhibit 
PT pore formation, while others anT inhibitors 
promote it. Because the anT is clearly involved 
in controlling the PT pore and hence in regula-
tion of apoptosis, it could be a target of appccl2p 
type metabolites of nnBPs such as clodronate. 
data indicate that the anT is indeed inhibited 
by appccl2p. By inhibiting anT, this metabo-
lite could also cause opening of the PT pore and 
hence cause apoptosis. The effect of anT inhibi-
tion on PT pore formation depends on whether the 
ligands bind to the m-state or the c-state. Ligands 
binding the m-state inhibit the formation of the 
PT pore and ligands binding to the c-state induce 
the formation of the PT pore. if appccl2p acts 
as an enhancer of PT pore formation, it would be 
expected to do this by acting as a ligand binding 
to the c-state of the anT. Thus, the pro-apoptotic 
effects of appccl2p may be similar to that of the 
other anT inhibitors. The concentration of ap-
pccl2p needed to affect the ANT (IC50=50 uM) 
and disrupt mitochondrial membrane potential 
is reasonably low.10, 11 as previously described, 
clodronate has been shown to be metabolized 
into the non-hydrolysable aTP analogue appc-
cl2p by aminoacyl-trna synthetase. Because of 
the similarities between aTP and this analogue, 
it has been found that this metabolite could act 
via the aTP-purinergic receptor pathway leading 
to an anabolic response. Once the drug has been 
lose their ruffled border and their normal cyto-
skeleton structure.4, 6
clodronate, that seems able to most closely 
mimic pyrophosphate, behaves as inorganic py-
rophosphate analogue by being metabolically 
incorporated into non-hydrolysable analogues 
of aTP though the reversal of the actions of 
aminoacyl-trna synthetases. The resulting me-
tabolites contain the P-c-P moiety in place of the 
β,γ-phosphate groups of ATP, thus resulting in 
non-hydrolysable nucleotides.7, 8 it is likely that 
intracellular accumulation of these metabolites 
within osteoclasts inhibits their function and may 
cause osteoclast cell death, probably by interfer-
ence with mitochondrial aTP translocases.9, 10 
nnBPs, such as clodronate, therefore appear to 
act essentially as prodrugs, being converted to 
active drug metabolites following intracellular 
uptake by osteoclasts in-vivo.
Figure 1 summarizes the mechanism of action 
of clodronate. Once absorbed, the drug enters in 
macrophages by endocytosis process, and then is 
metabolized to appccl2p (a non-hydrolysable 
aTP analogue) by aminoacyl-trna synthetase. 
This metabolite shows immediate effects on mi-
tochondrial membrane potential, and also causes 
cellular apoptosis.9 a biphasic effect on mito-
chondrial membrane potential has been observed. 
The direction of the initial change (increase in 
membrane potential) suggests that appccl2p 
somehow inhibits his dissipation. The electrogen-
ic ADP/ATP translocase (ANT) is one consumer 
of the membrane potential. inhibition of the anT 
would therefore account for the initial rise in 
Figure 1.—Mechanism of action of clodronate (from Savio-
la et al.,3 courtesy of Biolife Sas).
Bone matrix
appccl2p
aminoacyl-trna
synthetase
aTP
aTP
aTP
Osteoclast
clodronate
Mitochondrion
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but not for other tissues, their main cellular targets 
being mesenchymal cells, osteocytes, osteoblasts, 
and osteoclast precursors. These agents have the 
ability to increase bone mineral density (BMD), 
reduce bone turnover markers, and ultimately de-
crease the risk of osteoporotic fractures.16, 17
In-vitro studies have demonstrated the ability 
of clodronate in inhibiting reversibly the growth 
and glycolysis of fibroblasts and osteoclasts. In-
hibition of osteoclastic activity reduces the fir-
ing rate of new bone remodeling units, with an 
altered balance between bone formation and re-
sorption in favor of the latter, accounting for the 
effects of clodronate in the prevention and treat-
ment of postmenopausal osteoporosis.17
The efficacy of clodronate in the management 
of osteoporosis in postmenopausal women has 
been documented in several studies carried across 
more than two decades, which have shown the 
effects of clodronate administered using differ-
ent routes of administration and dose schedules, 
not only in increasing BMd, but also in reducing 
fragility-related fractures. Table i 18-34 summa-
rizes the results of studies with clodronate in the 
treatment of post-menopausal osteoporosis.
Effects of clodronate on BMD in patients with os-
teoporosis
In the first study data carried out in 1993,18 post-
menopausal women with OP were treated with 
oral clodronate every two months at a dose of 400 
mg/day, taken for 12 months. BMd increased 
significantly at the lumbar spine compared with 
untreated patients, in which BMd decreased by 
about 2%, and these positive effects were already 
significant after the first 6 months of therapy. 
The same study group compared the continuous 
and the cyclical (30-day on followed by 60-day 
off) regimen of oral clodronate 400 mg/day in 
postmenopausal OP,20 and found that clodronate 
induced a gain in bone mass, especially in the 
spine. However, the continuous regimen did not 
result in any further benefit in lumbar bone den-
sity over the cyclical one, probably because of a 
greater suppression of bone turnover.
in a double-blind, placebo-controlled trial,27 
593 women with postmenopausal (N.=483) or 
secondary (N.=110) osteoporosis were evaluated 
for three years. The oral administration of clo-
absorbed from chondrocytes (by pinocytosis) and 
metabolized, is then released by pannexin-1 he-
mi-channel in the extracellular space. next step 
is its bond to purinergic P2 receptors, such as P2X 
and P2Y receptors, on articular chondrocyte’s sur-
face. chondrocytes utilize the purinergic receptor 
pathway as a part of the mechano-transduction 
cascade in which aTP is released through con-
nexin-43, pannexin-1 hemi-channels and/or anK 
into the extracellular space, where it can bind and 
signal through a variety of purinergic P2 recep-
tors. P2Y receptors are G protein coupled recep-
tors which utilize iP3-ca2+ second messenger 
system, leading to the stimulation of extracellular 
matrix (ECM) gene expression and protein syn-
thesis, such as collagen and proteoglycans, while 
P2X receptors may have both catalytic func-
tions and regulate hemi-channel activity, through 
their interaction with pannexins. Stimulation by 
clodronate resulted in a 3-fold increase in ca2+ 
signalling and anabolic effects on cartilaginous 
ecM biosynthesis. as approximately 70% of 
clodronate-induced ca2+ signalling was abolished 
by inhibiting P2X receptors, this suggests that the 
released appccl2p may bind to the P2X7 or P2Y4 
receptor leading to additional release through its 
known association with pannexin-1. extracellu-
lar appccl2p then binds to P2Y receptors (most 
likely P2Y2) leading to the release of intracellular 
calcium from intracellular stores trough the iP3 
second messenger system.12, 13
Moreover, the drug shows anti-inflammatory 
and analgesic efficacy, which may be related to its 
pro-apoptotic action on macrophages, stopping 
their nitric oxide (NO) and pro-inflammatory 
cytokines (such as TNFα and IL 1β) release.9, 14 
all these molecules, secreted from damaged ar-
ticular chondrocytes during osteoarthritis early 
stages, also promote cartilage erosion and sub-
chondral bone alterations, and inhibit precursor 
maturation into chondrocytes. clodronate could 
therefore influence the natural history of this dis-
ease and stimulate chondrocytic differentiation 
by regulating inflammatory pathways.10, 13, 15
Clodronate in primary osteoporosis
BPs are the most well established class of drugs 
in the treatment of post-menopausal osteoporosis. 
BPs are characterized by a high affinity for bone 
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Table I.—Results of studies with clodronate in the treatment of primary osteoporosis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
Giannini et al., 199318 PM OP
60
a) Oral clodronate 400 mg daily for 30 days, followed by 60 days of no treatment 
(4 cycle repeated four times)
B) Oral calcitriol 2 µg for 5 days and oral clodronate 400 mg daily for additional 
25 days, followed by 60 days of no treatment (4 cycles)
c) no treatment
Lumbar BMD significantly increased at both 6 and 12 months of therapy in group A and B (+3.88±0.65% and +3.21±0.89%, 
respectively, at month 12), compared to a significant decline in untreated patients.
Filipponi et al., 199519 PM OP
124
a) i.v. clodronate 200 mg every month for 2 years
B) Transcutaneous 17-β-estradiol 50 μg daily for 2 years
c) Untreated controls
At 2 years, the mean spine BMD increased from baseline in group A (0.67±0.84%) compared to no substantial changes in group 
B (-0.14±0.93%) and decreased of more than 7% in untreated controls. A satisfactory change in BMD (<1%) was obtained in 
32% of the controls, in 79% of the estradiol group and in 90% of the clodronate-treated patients.
Giannini et al., 199620 PM OP
60
A) Oral clodronate 400 mg daily for 12 months (plus calcium)
B) Oral clodronate 400 mg daily for 30 days, followed by a 60-day period with 
calcium alone (up to 12 months)
c) calcium 1000 mg daily for 12 months
Patients in group C had a significant decline in spinal and femoral BMD, both at 6 and 12 months. Both clodronate-treated 
groups had increased levels of lumbar BMd compared with controls, both after 6 and 12 months. at the end of the study, 
patients in group B had higher spinal BMD compared with those of group A (3.32±0.71% vs. 0.43±0.89%, P<0.02). At 6 
months, femoral BMD was significantly higher in subjects treated with both cyclical and continuous clodronate compared to 
controls (P<0.01).
Filipponi et al., 199621 PM OP
235
(183 acted as 
retrospective 
controls)
i.v. clodronate 200 mg every 3 weeks for up to 6 years BMD increased significantly and the upward trend persisted for all 6 years of therapy (5.69±0.18%) vs. controls: -1.47±0.81%, 
P<0.0001). The increase in BMD was greater in the 145 patients without vertebral fractures before starting clodronate. From 
year 3 onward clodronate reduced the incidence of new vertebral fractures. in patients and controls monitored for 3 and 4 years, 
respectively, the number of patients developing new vertebral fractures fell significantly in the clodronate group (P=0.067 and 
P<0.003, respectively).
Heikkinen et al., 199722 PM women
107
a) i.v. clodronate 150 mg once weekly for 3 weeks
B) i.v. clodronate 300 mg once weekly for 3 weeks
c) i.v. clodronate 600 mg once weekly for 3 weeks
d) i.v. etidronate 300 mg once weekly for 3 weeks
e) i.v. placebo once weekly for 3 weeks
During the first year, 300 mg of clodronate retarded bone loss significantly in the lumbar spine and femoral neck, where 
significant protection still persisted after 24 months. Other doses of clodronate (150 and 600 mg) were not bone protective. 
Etidronate (300 mg) retarded bone loss significantly in the lumbar spine up to 24 months, relative to placebo.
rossini et al., 199923 PM OP
90
a) i.m. clodronate 100 mg every two weeks for 3 years
B) i.m. clodronate 100 mg every week for 3 years
c) Untreated controls
In group B, spinal BMD rose by 3.8±7.3% at the 6th month and, at the completion of 3 years of observation, the mean gain 
was 4.5±-6.3%. In group A, the increase in BMD was somewhat lower and slower, becoming significant only at month 24 
(2.9±4.6%). The femoral neck BMD did not change significantly during the 3 years of the study in none of the clodronate 
groups. In control group, a progressive, slow decline in spine and femoral BMD, which was statistically significant at the end 
of the second year of observation, was observed. In both treated groups, the hip BMD changes were significantly different from 
those in control group.
Filipponi et al., 200024 PM OP
120
a) Oral clodronate 400 mg for 2 years
B) i.m. clodronate 100 mg every 10 days for 2 years
c) i.v. clodronate 1800 mg in one single infusion every 6 months for 2 years
d) i.v. clodronate 300 mg in 6 consecutive days every 6 months for 2 years
e) Untreated controls
After 2 years, continuous clodronate regimens (group A and B) caused an increase in BMD both at lumbar spine (2.69% and 
3.07%, respectively) and proximal femur (2.09% and 2.12, respectively). Intermittent clodronate administration (group C and 
D) was associated with a small increase or a stabilization in BMD (0.53% and 1.22% at lumbar spine and 0.30% and 0.77% 
at femoral neck, respectively). From the 12th month, changes in spine and femoral neck BMd after continuous regimens were 
statistically higher compared to intermittent regimens.
Gnudi et al., 200125 PM OP
36
A) i.m. clodronate 100 mg every 10 days for 2 years (plus calcium)
B) calcium only every 10 days for 2 years
In the control group a progressive but not statistically significant decrease in BMD was observed in the spine and femoral 
neck over the 2-year follow-up. In contrast, patients treated with clodronate had a statistically significant increase in BMD in 
the spine at the first yearly check-up (2.63%) and a further but not statistically significant increase during the second year of 
treatment (0.59%). The increase in BMD at the femoral neck was not statistically significant during the first and second years of 
treatment, being 1.21% and 0.37% respectively.
celi et al., 200326 PM OP
84
A) i.v. clodronate 300 mg every 2 weeks for 2 years (plus calcium/vitamin D)
B) i.v. clodronate 100 mg weekly for 2 years (plus calcium/vitamin D)
c) calcium/vitamin d
In groups A and B, a significantly greater (P<0.05) increase in the lumbar BMD with respect to group C was observed after 6 
months of treatment. After 12 months of therapy, in group A the lumbar BMD (1.8%±0.5%) was significantly higher (P<0.05) 
than that in group B (0.9±0.3%). At the end of the study, in groups A (1.2±0.5%) and B (1.1±-0.4%) the percentage increase in 
the femoral neck BMD was significantly greater (P<0.05) than in group C (0.6±0.5%). After 24 months of therapy, there was no 
difference in the femoral neck BMd between groups a and B.
Mccloskey et al., 200427 PM or 
secondary OP
593
a) Oral clodronate 800 mg daily for 3 years
B) Oral placebo daily for 3 years
Treatment with clodronate was associated with a significant increase from baseline in mean spine BMD over 3 years 
(4.35±6.34% vs. 0.64±6.02% in the placebo group, P<0.0001). At the hip, clodronate maintained total BMD, whereas a 
significant decrease was observed in the placebo group (percent change from baseline 0.70±5.67% vs. -3.03±6.32% in the 
placebo group, P<0.0001). Incident vertebral fractures at 3 years were observed in 63 women (23.3%) in the placebo group and 
33 patients (12.7%) receiving clodronate (relative risk, 0.54; 95% CI, 0.37-0.80; P=0.001). Clodronate significantly reduced the 
risk of vertebral fracture in both post-menopausal and secondary OP subgroups, and in women with or without prior vertebral 
fracture at baseline.
Muscoso et al., 200428 elderly PM OP 
2000
a) i.m. clodronate 100 mg weekly for 2 years
B) Oral alendronate 10 mg daily for 2 years
c) Oral risedronate 5 mg daily for 2 years
d) Oral raloxifene 60 mg daily for 2 years
A significant increase in BMD after a 24-month treatment period was observed in the BPs groups. A total of 18 osteoporosis-
related fractures were observed during the entire study period; 10 out of 18 fractures occurred in the alendronate group, whereas 
the remaining 8 fractures were observed in the clodronate group.
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Table I.—Results of studies with clodronate in the treatment of primary osteoporosis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
Giannini et al., 199318 PM OP
60
a) Oral clodronate 400 mg daily for 30 days, followed by 60 days of no treatment 
(4 cycle repeated four times)
B) Oral calcitriol 2 µg for 5 days and oral clodronate 400 mg daily for additional 
25 days, followed by 60 days of no treatment (4 cycles)
c) no treatment
Lumbar BMD significantly increased at both 6 and 12 months of therapy in group A and B (+3.88±0.65% and +3.21±0.89%, 
respectively, at month 12), compared to a significant decline in untreated patients.
Filipponi et al., 199519 PM OP
124
a) i.v. clodronate 200 mg every month for 2 years
B) Transcutaneous 17-β-estradiol 50 μg daily for 2 years
c) Untreated controls
At 2 years, the mean spine BMD increased from baseline in group A (0.67±0.84%) compared to no substantial changes in group 
B (-0.14±0.93%) and decreased of more than 7% in untreated controls. A satisfactory change in BMD (<1%) was obtained in 
32% of the controls, in 79% of the estradiol group and in 90% of the clodronate-treated patients.
Giannini et al., 199620 PM OP
60
A) Oral clodronate 400 mg daily for 12 months (plus calcium)
B) Oral clodronate 400 mg daily for 30 days, followed by a 60-day period with 
calcium alone (up to 12 months)
c) calcium 1000 mg daily for 12 months
Patients in group C had a significant decline in spinal and femoral BMD, both at 6 and 12 months. Both clodronate-treated 
groups had increased levels of lumbar BMd compared with controls, both after 6 and 12 months. at the end of the study, 
patients in group B had higher spinal BMD compared with those of group A (3.32±0.71% vs. 0.43±0.89%, P<0.02). At 6 
months, femoral BMD was significantly higher in subjects treated with both cyclical and continuous clodronate compared to 
controls (P<0.01).
Filipponi et al., 199621 PM OP
235
(183 acted as 
retrospective 
controls)
i.v. clodronate 200 mg every 3 weeks for up to 6 years BMD increased significantly and the upward trend persisted for all 6 years of therapy (5.69±0.18%) vs. controls: -1.47±0.81%, 
P<0.0001). The increase in BMD was greater in the 145 patients without vertebral fractures before starting clodronate. From 
year 3 onward clodronate reduced the incidence of new vertebral fractures. in patients and controls monitored for 3 and 4 years, 
respectively, the number of patients developing new vertebral fractures fell significantly in the clodronate group (P=0.067 and 
P<0.003, respectively).
Heikkinen et al., 199722 PM women
107
a) i.v. clodronate 150 mg once weekly for 3 weeks
B) i.v. clodronate 300 mg once weekly for 3 weeks
c) i.v. clodronate 600 mg once weekly for 3 weeks
d) i.v. etidronate 300 mg once weekly for 3 weeks
e) i.v. placebo once weekly for 3 weeks
During the first year, 300 mg of clodronate retarded bone loss significantly in the lumbar spine and femoral neck, where 
significant protection still persisted after 24 months. Other doses of clodronate (150 and 600 mg) were not bone protective. 
Etidronate (300 mg) retarded bone loss significantly in the lumbar spine up to 24 months, relative to placebo.
rossini et al., 199923 PM OP
90
a) i.m. clodronate 100 mg every two weeks for 3 years
B) i.m. clodronate 100 mg every week for 3 years
c) Untreated controls
In group B, spinal BMD rose by 3.8±7.3% at the 6th month and, at the completion of 3 years of observation, the mean gain 
was 4.5±-6.3%. In group A, the increase in BMD was somewhat lower and slower, becoming significant only at month 24 
(2.9±4.6%). The femoral neck BMD did not change significantly during the 3 years of the study in none of the clodronate 
groups. In control group, a progressive, slow decline in spine and femoral BMD, which was statistically significant at the end 
of the second year of observation, was observed. In both treated groups, the hip BMD changes were significantly different from 
those in control group.
Filipponi et al., 200024 PM OP
120
a) Oral clodronate 400 mg for 2 years
B) i.m. clodronate 100 mg every 10 days for 2 years
c) i.v. clodronate 1800 mg in one single infusion every 6 months for 2 years
d) i.v. clodronate 300 mg in 6 consecutive days every 6 months for 2 years
e) Untreated controls
After 2 years, continuous clodronate regimens (group A and B) caused an increase in BMD both at lumbar spine (2.69% and 
3.07%, respectively) and proximal femur (2.09% and 2.12, respectively). Intermittent clodronate administration (group C and 
D) was associated with a small increase or a stabilization in BMD (0.53% and 1.22% at lumbar spine and 0.30% and 0.77% 
at femoral neck, respectively). From the 12th month, changes in spine and femoral neck BMd after continuous regimens were 
statistically higher compared to intermittent regimens.
Gnudi et al., 200125 PM OP
36
A) i.m. clodronate 100 mg every 10 days for 2 years (plus calcium)
B) calcium only every 10 days for 2 years
In the control group a progressive but not statistically significant decrease in BMD was observed in the spine and femoral 
neck over the 2-year follow-up. In contrast, patients treated with clodronate had a statistically significant increase in BMD in 
the spine at the first yearly check-up (2.63%) and a further but not statistically significant increase during the second year of 
treatment (0.59%). The increase in BMD at the femoral neck was not statistically significant during the first and second years of 
treatment, being 1.21% and 0.37% respectively.
celi et al., 200326 PM OP
84
A) i.v. clodronate 300 mg every 2 weeks for 2 years (plus calcium/vitamin D)
B) i.v. clodronate 100 mg weekly for 2 years (plus calcium/vitamin D)
c) calcium/vitamin d
In groups A and B, a significantly greater (P<0.05) increase in the lumbar BMD with respect to group C was observed after 6 
months of treatment. After 12 months of therapy, in group A the lumbar BMD (1.8%±0.5%) was significantly higher (P<0.05) 
than that in group B (0.9±0.3%). At the end of the study, in groups A (1.2±0.5%) and B (1.1±-0.4%) the percentage increase in 
the femoral neck BMD was significantly greater (P<0.05) than in group C (0.6±0.5%). After 24 months of therapy, there was no 
difference in the femoral neck BMd between groups a and B.
Mccloskey et al., 200427 PM or 
secondary OP
593
a) Oral clodronate 800 mg daily for 3 years
B) Oral placebo daily for 3 years
Treatment with clodronate was associated with a significant increase from baseline in mean spine BMD over 3 years 
(4.35±6.34% vs. 0.64±6.02% in the placebo group, P<0.0001). At the hip, clodronate maintained total BMD, whereas a 
significant decrease was observed in the placebo group (percent change from baseline 0.70±5.67% vs. -3.03±6.32% in the 
placebo group, P<0.0001). Incident vertebral fractures at 3 years were observed in 63 women (23.3%) in the placebo group and 
33 patients (12.7%) receiving clodronate (relative risk, 0.54; 95% CI, 0.37-0.80; P=0.001). Clodronate significantly reduced the 
risk of vertebral fracture in both post-menopausal and secondary OP subgroups, and in women with or without prior vertebral 
fracture at baseline.
Muscoso et al., 200428 elderly PM OP 
2000
a) i.m. clodronate 100 mg weekly for 2 years
B) Oral alendronate 10 mg daily for 2 years
c) Oral risedronate 5 mg daily for 2 years
d) Oral raloxifene 60 mg daily for 2 years
A significant increase in BMD after a 24-month treatment period was observed in the BPs groups. A total of 18 osteoporosis-
related fractures were observed during the entire study period; 10 out of 18 fractures occurred in the alendronate group, whereas 
the remaining 8 fractures were observed in the clodronate group.
 (To be continued) 
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another open-label study21 evaluated the 
changes in BMd in 235 postmenopausal women 
with osteoporosis treated every 3 weeks with 
200 mg of clodronate i.v. and followed annually 
for six years, compared with a control group of 
183 women observed retrospectively. The results 
showed a significant increase in BMD in the 
first year of treatment, and the effect was main-
tained over six years. Based on these results, a 
subsequent study conducted by the same group24 
evaluated the administration of clodronate con-
tinuously (oral or i.m.) or intermittently (i.v.). 
continuous clodronate regimens determined an 
increase in both lumbar spine and proximal fe-
mur BMd, whereas intermittent clodronate ad-
ministration was associated with a small increase 
or a stabilization in bone mass.
When given i.v. at a dose of 300 mg infused 
3 times in one-week intervals, clodronate was 
dronate at a dose of 800 mg/day was associated 
with a significant increase in BMD at the lumbar 
spine and total hip compared with placebo. at the 
same oral dosage of 800 mg/day, clodronate was 
shown to reduce the loss of femoral bone mass 
in a large institutionalized elderly population.30
Further confirmation of the effectiveness of 
oral clodronate 800 mg/day on BMd has been 
reported in a small randomised clinical trial last-
ing three years conducted in postmenopausal os-
teoporosis women.31
Several studies have evaluated the effects 
of parenteral administration of clodronate. in a 
comparative study vs. transcutaneous 17-beta-
estradiol (50 µg daily) and untreated controls,19 
treatment with i.v. clodronate 200 mg/month for 
2 years was associated with an increase in spine 
BMd compared to no changes in the estradiol 
group and a decrease in controls.
Table I.—Results of studies with clodronate in the treatment of primary osteoporosis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
dominguez et al., 200529 PM OP
250
A) i.m. clodronate 100 mg weekly for 12 months (plus calcium/vitamin D)
B) i.m. clodronate 100 mg every two weeks for 12 months (plus calcium/vitamin D)
c) calcium/vitamin d only
A significant increase in mean BMD was observed at the lumbar spine in patients receiving clodronate (4.21% in group A and 
2.98% in group B), whereas no significant changes were reported in patients receiving only calcium and vitamin D (-0.50%). 
The difference between groups A and B was statistically significant at both the lumbar spine (P=0.02) and the femoral neck 
(P=0.05). Increases at all femoral sites were also observed in the clodronate groups.
Mccloskey et al., 200730 elderly women
5579
A) Oral clodronate 800 mg daily for 3 years (plus calcium)
B) Oral placebo daily for 3 years (plus calcium)
A new hip fracture during the 3-year treatment phase occurred in 56 (2.0%) women in the clodronate group and in 58 (2.1%) in 
the placebo group (hazard ratio [HR], 1.02; 95% CI, 0.71-1.47). Clodronate did, however, decrease the incidence of any clinical 
fracture by 20% (264 women [9.5%] versus 337 [12.1%] in the placebo group; HR, 0.80; 95% CI, 0.68-0.94). The incidence of 
OP-associated non-hip fractures was also significantly decreased by 29% in the clodronate group (5.2% versus 7.4%; Hr, 0.71; 
95% ci, 0.57-0.87). in women with hip measurements, the mean decrease in BMd was 61% lower in the clodronate group 
compared to placebo.
Tanakol et al., 200731 PM OP
89
A) Oral clodronate 800 mg daily for 3 years (plus calcium/vitamin D)
B) calcium/vitamin d only
Treatment with clodronate significantly increased mean femoral neck BMD by 3.2±2.9%, trochanter BMD by 2.2±2.9% and 
lumbar spine BMD by 3.1±3%. In the control group, femoral neck, trochanter and lumbar spine BMD decreased by -6±2.7%, 
-7.3±2.5% and -5.4±2%, respectively (P<0.01, P<0.05 and P<0.05 between groups, respectively).
Muratore et al., 201032 PM OP
60
a) i.m. clodronate 100 mg weekly for 12 months
B) i.m. clodronate 200 mg every two weeks for 12 months
A significant increase of lumbar and femoral BMD at 12 months vs. baseline was reported in both groups. in group a 
lumbar BMd increased by 3.5% and femoral BMd by 2.1%; in group B, lumbar and femoral BMd rose by 3.4% and 2.2%, 
respectively. No difference was observed between groups. Bone resorption markers significantly decreased from baseline.
Frediani, 201133 PM OP
60
a) i.m. clodronate 100 mg weekly for 2 years
B) i.m. clodronate 200 mg every two weeks for 2 years
Significant increases in mean BMD of the lumbar spine versus baseline were observed in both groups at 1 and 2 years (group 
A - year 1: 2.8±1.7%, P<0.05; year 2: 3.5±2.2%, P<0.01; group B - year 1: 2.7±2.1%, P<0.05; year 2: 3.9 ± 2.2%, P<0.01). 
Mean BMD at the femoral neck also significantly increased versus baseline in group A at both time-points (year 1: 2.3±1.9%, 
P<0.05; year 2: 2.5±1.9%, P<0.05), while the increase in group B was significant only at 2 years (year 1: 1.9±2.2%; year 2: 
2.8 ± 1.8%; P<0.05). Significant increases in total femur BMD were observed only in group A at 2 years (2.4±1.9%, P<0.05). 
no differences between groups were reported.
Frediani et al., 201334 PM OP
60
a) i.m. clodronate 100 mg weekly for 2 years
B) i.m. clodronate 100 mg twice weekly for 2 years
Significant increases vs. baseline in BMD were observed in both groups at 1 and 2 years, with significantly higher increases in 
group B compared to group A. The increase in BMD at the lumbar spine in group B was 4.0±2.1% and 5.9±2.0 at 1 and 2 years, 
respectively, compared with 2.8±1.7 and 3.5±2.2%, respectively, in group A. Similarly, group B had a greater increase of BMD 
at femoral neck (3.5±1.7% and +5.4±1.8% at 1 and 2 years, respectively), compared with a change of 2.3±1.9% and 2.5±1.9%, 
respectively, in group A. The BMD increase measured at the total femur was also significantly higher for Group B (3.4±1.9% 
and 4.9±2.1% at years 1 and 2, respectively) compared to group A (1.6±0.9% and 2.4±1.9% at years 1 and 2, respectively).
PM: postmenopausal; OP: osteoporosis; BMd: bone mineral density; i.v.: intravenous; i.m.: intramuscular; Hr: hazard ratio.
 (continues).
Th
is 
do
cu
m
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
at
io
na
l c
op
yr
ig
ht
 la
ws
. N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
 It
 is
 p
er
m
itt
ed
 fo
r p
er
so
na
l u
se
 to
 d
ow
nl
oa
d 
an
d 
sa
ve
 o
nl
y 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
. I
t i
s 
no
t p
er
m
itt
ed
 to
 m
ak
e 
ad
di
tio
na
l c
op
ie
s 
(e
ith
er
 s
po
ra
di
ca
lly
 
or
 s
ys
te
m
at
ica
lly
, e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c)
 o
f t
he
 A
rti
cle
 fo
r a
ny
 p
ur
po
se
. I
t i
s 
no
t p
er
m
itt
ed
 to
 d
ist
rib
ut
e 
th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cle
 th
ro
ug
h 
on
lin
e 
in
te
rn
et
 a
nd
/o
r i
nt
ra
ne
t fi
le
 s
ha
rin
g 
sy
st
em
s,
 e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
 m
ea
ns
 w
hi
ch
 m
ay
 a
llo
w 
ac
ce
ss
 
to
 th
e 
Ar
tic
le
. T
he
 u
se
 o
f a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cle
 fo
r a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
. T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e 
wo
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
. T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r p
er
so
na
l o
r c
om
m
er
cia
l u
se
 is
 n
ot
 p
er
m
itt
ed
. I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r, 
 o
ve
rla
y, 
ob
sc
ur
e,
 b
lo
ck
, o
r 
ch
an
ge
 a
ny
 c
op
yr
ig
ht
 n
ot
ice
s 
or
 te
rm
s 
of
 u
se
 w
hi
ch
 th
e 
Pu
bl
ish
er
 m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
. I
t i
s 
no
t p
er
m
itt
ed
 to
 fr
am
e 
or
 u
se
 fr
am
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
ad
em
ar
k,
 lo
go
, o
r 
ot
he
r 
pr
op
rie
ta
ry
 in
fo
rm
at
io
n 
of
 th
e 
Pu
bl
ish
er
.
cLOdrOnaTe in THe ManaGeMenT OF diFFerenT MUScULOSKeLeTaL cOndiTiOnS Frediani
vol. 109 - no. 4 Minerva Medica 307
shown to counteract postmenopausal bone loss 
for at least one year in the lumbar spine and up to 
two years in the femoral neck.22
in a comparative study26 of two different regi-
mens of i.v. clodronate (300 mg every two weeks 
and 100 mg/week) given in postmenopausal os-
teoporosis women intolerant to amino-BPs, both 
dose schedules were associated with significant 
increases in BMd at lumbar spine and femo-
ral neck up to 24 months, however with more 
marked effects at the lumbar spine with the 300 
mg dose every two weeks at 12 months.
Positive results have also emerged from the 
use of clodronate i.m. in the treatment of post-
menopausal osteoporosis. in 1999 rossini et 
al.23 showed that, after two years of treatment 
with clodronate i.m. at a dose of 100 mg every 
two weeks or every week (with oral calcium sup-
plementation), the treated group had significant 
increases in lumbar and femoral BMd compared 
with the control group (treated only with cal-
cium supplementation). Statistically significant 
increases in BMd at the lumbar spine were also 
observed when i.m. clodronate 100 mg was ad-
ministered every 10 days for 2 years.25
in a study in 250 postmenopausal women, 
dominguez et al. compared weekly i.m. admin-
istration of clodronate 100 mg with the same 
dose given every two weeks, and found that both 
regimens determined a statistically significant 
improvement in BMd compared with the con-
trol group treated only with calcium and vitamin 
d supplementation. nevertheless, the largest in-
creases in BMd at the lumbar spine and femo-
ral neck were reported in the group of patients 
treated with clodronate 100 mg per week.29
More recent trials have been conducted in 
women with postmenopausal osteoporosis to 
Table I.—Results of studies with clodronate in the treatment of primary osteoporosis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
dominguez et al., 200529 PM OP
250
A) i.m. clodronate 100 mg weekly for 12 months (plus calcium/vitamin D)
B) i.m. clodronate 100 mg every two weeks for 12 months (plus calcium/vitamin D)
c) calcium/vitamin d only
A significant increase in mean BMD was observed at the lumbar spine in patients receiving clodronate (4.21% in group A and 
2.98% in group B), whereas no significant changes were reported in patients receiving only calcium and vitamin D (-0.50%). 
The difference between groups A and B was statistically significant at both the lumbar spine (P=0.02) and the femoral neck 
(P=0.05). Increases at all femoral sites were also observed in the clodronate groups.
Mccloskey et al., 200730 elderly women
5579
A) Oral clodronate 800 mg daily for 3 years (plus calcium)
B) Oral placebo daily for 3 years (plus calcium)
A new hip fracture during the 3-year treatment phase occurred in 56 (2.0%) women in the clodronate group and in 58 (2.1%) in 
the placebo group (hazard ratio [HR], 1.02; 95% CI, 0.71-1.47). Clodronate did, however, decrease the incidence of any clinical 
fracture by 20% (264 women [9.5%] versus 337 [12.1%] in the placebo group; HR, 0.80; 95% CI, 0.68-0.94). The incidence of 
OP-associated non-hip fractures was also significantly decreased by 29% in the clodronate group (5.2% versus 7.4%; Hr, 0.71; 
95% ci, 0.57-0.87). in women with hip measurements, the mean decrease in BMd was 61% lower in the clodronate group 
compared to placebo.
Tanakol et al., 200731 PM OP
89
A) Oral clodronate 800 mg daily for 3 years (plus calcium/vitamin D)
B) calcium/vitamin d only
Treatment with clodronate significantly increased mean femoral neck BMD by 3.2±2.9%, trochanter BMD by 2.2±2.9% and 
lumbar spine BMD by 3.1±3%. In the control group, femoral neck, trochanter and lumbar spine BMD decreased by -6±2.7%, 
-7.3±2.5% and -5.4±2%, respectively (P<0.01, P<0.05 and P<0.05 between groups, respectively).
Muratore et al., 201032 PM OP
60
a) i.m. clodronate 100 mg weekly for 12 months
B) i.m. clodronate 200 mg every two weeks for 12 months
A significant increase of lumbar and femoral BMD at 12 months vs. baseline was reported in both groups. in group a 
lumbar BMd increased by 3.5% and femoral BMd by 2.1%; in group B, lumbar and femoral BMd rose by 3.4% and 2.2%, 
respectively. No difference was observed between groups. Bone resorption markers significantly decreased from baseline.
Frediani, 201133 PM OP
60
a) i.m. clodronate 100 mg weekly for 2 years
B) i.m. clodronate 200 mg every two weeks for 2 years
Significant increases in mean BMD of the lumbar spine versus baseline were observed in both groups at 1 and 2 years (group 
A - year 1: 2.8±1.7%, P<0.05; year 2: 3.5±2.2%, P<0.01; group B - year 1: 2.7±2.1%, P<0.05; year 2: 3.9 ± 2.2%, P<0.01). 
Mean BMD at the femoral neck also significantly increased versus baseline in group A at both time-points (year 1: 2.3±1.9%, 
P<0.05; year 2: 2.5±1.9%, P<0.05), while the increase in group B was significant only at 2 years (year 1: 1.9±2.2%; year 2: 
2.8 ± 1.8%; P<0.05). Significant increases in total femur BMD were observed only in group A at 2 years (2.4±1.9%, P<0.05). 
no differences between groups were reported.
Frediani et al., 201334 PM OP
60
a) i.m. clodronate 100 mg weekly for 2 years
B) i.m. clodronate 100 mg twice weekly for 2 years
Significant increases vs. baseline in BMD were observed in both groups at 1 and 2 years, with significantly higher increases in 
group B compared to group A. The increase in BMD at the lumbar spine in group B was 4.0±2.1% and 5.9±2.0 at 1 and 2 years, 
respectively, compared with 2.8±1.7 and 3.5±2.2%, respectively, in group A. Similarly, group B had a greater increase of BMD 
at femoral neck (3.5±1.7% and +5.4±1.8% at 1 and 2 years, respectively), compared with a change of 2.3±1.9% and 2.5±1.9%, 
respectively, in group A. The BMD increase measured at the total femur was also significantly higher for Group B (3.4±1.9% 
and 4.9±2.1% at years 1 and 2, respectively) compared to group A (1.6±0.9% and 2.4±1.9% at years 1 and 2, respectively).
PM: postmenopausal; OP: osteoporosis; BMd: bone mineral density; i.v.: intravenous; i.m.: intramuscular; Hr: hazard ratio.
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teoporosis-associated non-hip fractures was also 
significantly decreased by 29% in the clodronate 
group compared to placebo (5.2% vs. 7.4%).
another study in elderly patients has demon-
strated the anti-fracture efficacy of i.m. clodro-
nate compared with other BPs, including alen-
dronic acid.28 notably, in this study improve-
ments in BMd were poor predictive of the risk of 
new fractures, which resulted to be age-related.
The results of a recent meta-analysis have 
demonstrated that clodronate is effective in re-
ducing the risk of vertebral, non-vertebral, and 
overall fractures in patients with skeletal fragility 
due to intense osteoclast activity, such as cancer 
diseases, multiple myeloma, post-menopausal 
and secondary OP.35
Clodronate in secondary osteoporosis
The heterogeneous group of secondary osteopo-
rosis includes all cases of osteoporosis in which 
other causes to menopause and aging are identi-
fied, and may be the result of one or more of the 
following factors: systemic diseases, endocrine 
diseases, gastro-intestinal diseases, malignant 
neoplasms and other hematologic conditions, 
chronic use of glucocorticoids and other drugs, 
lifestyle conditions and habits.
Effects of clodronate in glucocorticoid-induced os-
teoporosis
Glucocorticosteroid-induced osteoporosis (GIOP) 
is the most common form of secondary osteopo-
rosis and the first iatrogenic cause of osteopo-
rosis. Bone loss and increased rate of fractures 
occur early after the initiation of corticosteroid 
therapy, and are related to dosage and treatment 
duration. response to treatment of GiOP is not 
different from that of postmenopausal osteoporo-
sis and therefore antiresorptive therapy including 
BPs remains the first therapeutic option.36
different trials have shown the effects of clo-
dronate, in any of the available formulations 
(oral, i.m. and i.v.), in preventing bone loss or 
increasing bone mass in patients with GiOP 
(Table II).37-51 The first study40 was conducted 
in 74 adult asthmatic patients with a long his-
tory of continuous oral and inhaled corticoste-
roid administration, who were assigned to treat-
assess the most appropriate schedule regimen 
in the administration of i.m. clodronate and 
hence to evaluate whether less frequent dosing 
regimens may promote an improved adherence 
to treatment while maintaining the same effi-
cacy. Similarity of effects on BMd increase at 
12 months between the i.m. clodronate 200 mg 
twice-a-month and the 100 mg/week regimens 
(i.e. at the same overall dose) has been shown 
in the first of these studies.32 another study33 
that tested the same dosing regimens, in which 
the clodronate 200 mg every 2 weeks dose was 
given in two 100 mg injections on two consecu-
tive days, confirmed the similarity of effects on 
BMd at lumbar spine and femoral neck between 
the new proposed dose schedule and the 100 mg/
week regimen. in another study in postmeno-
pausal osteoporosis, the same author reported a 
superior increase of lumbar and femoral BMd 
of i.m. clodronate 200 mg/week (100 mg twice 
weekly) over the 100 mg once/week regimen,34 
thus suggesting a dose-dependent densitometric 
effect of i.m. clodronate.
Effects on fracture risk in patients with osteoporosis
The effects of clodronate in reducing the inci-
dence of vertebral fractures were first observed 
in the study published in 1996,21 in which long-
term treatment with i.v. clodronate 200 mg ev-
ery 3 weeks was associated with a significant 
reduction in incidence of vertebral fractures 
compared to controls, which was more evident 
in the subgroup that did not present fractures at 
baseline.
The efficacy of oral clodronate in reducing the 
risk of skeletal fractures was demonstrated in the 
3-years double-blind trial of Mccloskey et al.,27 
in which the incidence of vertebral fractures was 
reduced by 46% in the clodronate group com-
pared to placebo. This reduction reached statisti-
cal significance after one year of therapy.
in the randomized controlled trial involving 
5592 institutionalised women aged ≥75 years,30 
56 patients (2.0%) in the clodronate group and 
58 (2.1%) in the placebo group had a new hip 
fracture during the 3-year treatment phase. 
However, clodronate reduced the incidence of 
any clinical fracture by 20% relative to placebo 
(9.5% vs. 12.1%), as well as the incidence of os-
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um/vitamin d supplementation alone, for 4 years. 
BMD did not change significantly in the clodro-
nate plus calcium and vitamin d group, whereas 
it declined significantly in the control group. The 
difference between groups at 48 months was sig-
nificant for BMD at lumbar spine, femoral neck, 
trochanter, total femur and total body. The rela-
tive risk of vertebral fractures and multiple ver-
tebral fractures in the clodronate group compared 
to the calcium plus vitamin d group was 0.63 and 
0.25, respectively. The overall risk reduction was 
evident in both premenopausal (relative risk 0.56) 
and postmenopausal women (0.65). This is the 
only study demonstrating that intermittent i.m. 
administration of clodronate once weekly was ef-
fective in preventing vertebral fractures in GiOP.
Secondary osteoporosis can develop in pa-
tients with significant gastrointestinal failure 
and malabsorption, especially in those requiring 
parenteral nutrition. although the exact cause 
of bone loss in patients undergoing parenteral 
nutrition is not known, it is believed that it has 
a multifactorial origin, with factors including 
underlying disease, effect of medications used 
to treat this disease (e.g. corticosteroids), and 
various components of the parenteral nutrition 
solution.53 in a placebo-controlled trial44 in 20 
patients receiving home parenteral nutrition and 
low BMd, in which i.v. clodronate 1500 mg was 
given every three months for one year, mean 
BMd at lumbar spine increased from baseline 
to end of treatment in the clodronate group and 
decreased in the placebo group, however not sig-
nificantly between groups. BMD at the other sec-
ondary skeletal sites increased in the clodronate 
group. Treatment with clodronate was also asso-
ciated with significant decreases in biochemical 
markers of bone resorption. although conducted 
in a small number of patients, this study showed 
preliminary evidence that i.v. clodronate at the 
tested dosage may produce significant suppres-
sion of bone resorption in patients requiring par-
enteral therapy.
clodronate i.m. or i.v has been successfully 
used also for the management of thalassemia-
associated osteoporosis, which represents one 
of the most complex and obstinate form of sec-
ondary osteoporosis. in general, patients with 
thalassemia-associated osteoporosis respond 
ment with three different daily doses of clodro-
nate (800, 1600 or 2400 mg) or placebo, for 12 
months. Significant increases from baseline to 12 
month in BMd at lumbar spine were observed 
with clodronate 1600 and 2400 mg, with a sig-
nificant dose-response effect, and with clodro-
nate 2400 mg at the femoral neck and trochanter 
region. The i.m. formulation of clodronate in the 
treatment of GiOP was tested in another trial in 
60 asthmatic patients,41 who were treated with 
clodronate 100 mg every two weeks for one year. 
at the end of treatment, clodronate was effective 
in increasing BMd compared with baseline and 
compared with untreated controls, irrespective 
of the underlying inhaled corticosteroid therapy. 
in another trial47 conducted in 67 patients with 
inflammatory bowel disease (IBD) starting a ste-
roid therapy, treatment with i.v. clodronate 300 
mg once monthly for 3 months (900 mg in total) 
was associated with a stabilization of BMd at 
lumbar spine and femoral neck at one year, com-
pared to significant decreases of BMD at both 
skeletal sites in patients receiving placebo.
Effects of clodronate in other forms of secondary 
osteoporosis
in addition to the above-reported studies in GiOP, 
clodronate was also effective in the treatment of 
patients with subclinical cushing’s Syndrome 
(SCS) and osteoporosis or osteopenia,50 who 
were treated with i.m. 100 mg/week plus cal-
cium and vitamin d for 12 months or only with 
supplemental therapy. Patients treated with clo-
dronate had increased lumbar BMd, preserved 
bone mass at the femoral neck, stabilized ver-
tebral fracture index, and decreased subjective 
back pain, compared to increased bone loss and 
unchanged pain in the untreated control group.
BPs may be used in rheumatoid arthritis or in 
other inflammatory autoimmune joint diseases 
due to their effects on osteoclasts, which play a 
key role in the bone loss process that accompanies 
the joint damage in arthritis.52 The anti-inflamma-
tory effects of clodronate may add further benefi-
cial effects in the treatment of inflammatory joint 
diseases. in a study in 163 patients with rheuma-
toid or psoriatic arthritis starting steroid therapy,45 
who were randomised to receive i.m clodronate 
100 mg/week plus calcium and vitamin d or calci-
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Table II.—Results of studies with clodronate in the treatment of secondary osteoporosis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
rizzoli et al., 199637 Breast cancer
67
a) Oral clodronate 1600 mg daily for 9 months
B) Untreated controls
BMd at lumbar spine, femoral neck and midfemoral shaft slightly increased in the clodronate group, compared to small 
decreases in controls. In 15 women without evident lumbar spine bone metastasis (7 clodronate-treated and 8 controls), 
mean lumbar spine BMD increased vs. baseline in the clodronate group by +5.2±2.5% vs. -0.3±1.4%, and +8.1±4.7% vs. 
-0.9±1.7%, after 10.3±0.4 and 17.3±1.2 months, respectively (P<0.01). The rate of bone complications (pathological fracture, 
hypercalcemic episode, scintigraphic or radiological evidence of metastasis development, chemo- or radiotherapy for bone 
disease progression) was 28.8 events/100 patient/year in the clodronate group vs. 39.0 in controls, and 31.5 vs. 40.5, after 9 and 
15 months of follow-up, respectively.
Saarto et al., 199738 Breast cancer
121
A) Oral clodronate 1600 mg daily for 3 years (plus antiestrogens)
B) Untreated controls (antiestrogens only)
at 2 years, clodronate with antiestrogens markedly increased BMd in the lumbar spine and femoral neck by 2.9% and 3.7% 
(P=0.001 and P=0.006 respectively). There were no significant changes in BMD in the patients given antiestrogens only.
Saarto et al., 199739 Breast cancer
148
A) Oral clodronate 1600 mg daily for 2 years (plus chemotherapy)
B) Untreated controls (chemotherapy only)
Mean changes in BMd at lumbar spine and femoral neck were -5.9% and -2.0% without clodronate and -2.2% and +0.9% with 
clodronate at 2 years (P=0.0005 and 0.017, respectively). Patients who developed amenorrhea after chemotherapy had a rapid 
bone loss, which was significantly reduced by clodronate. In controls, bone loss was 9.5% at the lumbar spine and 4.6% at the 
femoral neck, while in the clodronate group, bone loss was 5.9% and 0.4%, respectively, at 2 years.
Herrala et al., 199840 GiOP in asthma
74
a) Oral clodronate 800 mg daily for 12 months
B) Oral clodronate 1600 mg daily for 12 months
c) Oral clodronate 2400 mg daily for 12 months
d) Placebo daily for 12 months
Mean BMD at lumbar spine increased significantly from baseline to month 12 in the clodronate groups of 1600 and 2400 mg/
day, i.e. 2.6% (P<0.02) and 3.0% (P<0.01), respectively, but not in the placebo and clodronate 800 mg/day groups. The test for 
a linear dose trend (lumbar spine BMD percent change) at 12 months was significant (P<0.02). The mean BMD at femoral neck 
increased significantly in the 2400 mg/day group, i.e. (4.3%, P<0.0001), as well as in the trochanter region (2.8%, P<0.02).
Muratore et al., 200041 GiOP in asthma
60
A) i.m. clodronate 100 mg every two weeks for one year (plus 
inhaled FP and oral calcium)
B) i.m. clodronate 100 mg every two weeks for one year (plus 
inhaled BdP and oral calcium)
C) Untreated controls (only inhaled FP and oral calcium)
D) Untreated controls (only inhaled BDP and oral calcium)
Mean BMD at lumbar level significantly increased from baseline to month 12 in the groups receiving clodronate and 
significantly decrease in groups not receiving clodronate. A statistically significant increase in mean BMD at month 12 was 
observed in groups a and B compared to groups c and d, respectively.
Saarto et al., 200142 
(follow-up of38)
Breast cancer
61
A) Oral clodronate 1600 mg daily for 3 years (plus antiestrogens)
B) Untreated controls (antiestrogens only)
Al 3 years, clodronate slightly increased BMD at lumbar spine (+1.0% vs. -1.7% in controls, P=0.01) and at femoral neck 
(+2.4% vs. -0.4%, P=0.12). at 5 years of follow-up, 2 years after the end of therapy, clodronate vs. controls was -1.0% vs. 
-3.2% (P=0.06) at lumbar spine and -0.1% vs. -5.2% (P=0.001) at femoral neck.
vehmanen et al., 200143 
(follow-up of39)
Breast cancer
73
A) Oral clodronate 1600 mg daily for 3 years (plus chemotherapy)
B) Untreated controls (chemotherapy only)
Clodronate significantly reduced the bone loss in the lumbar spine (-3.0%) compared with controls (-7.4%) at three years 
(P=0.003), but no significant difference was found in the femoral neck (-1.7% vs. -2.8%, P=0.86). These differences were still 
seen at 5 years: -5.8% vs. -9.7% at lumbar spine (P=0.008) and -3.5% vs. -5.1% at femoral neck (P=0.91).
Haderslev et al., 200244 HPn
20
a) i.v. clodronate 1500 mg every three months for one year
B) i.v. placebo every three months for one year
The mean BMD at lumbar spine increased by 0.8%±2.0% in the clodronate group and decreased by 1.6%±2.0% in the placebo 
group (P=0.43 between groups). At all secondary skeletal sites (hip, total body and distal forearm), there were small increases 
in the BMd in the clodronate group and decreases in the placebo group. Biochemical markers of bone resorption decreased 
significantly in the clodronate group (P<0.05).
Frediani et al., 200345 Prevention of GiOP in ra
163
A) i.m. clodronate 100 mg weekly for 48 months (plus calcium/
vitamin d)
B) calcium/vitamin d only
BMD did not change significantly in the clodronate group and declined significantly in control group. The difference between 
groups at 48 months in mean changes from baseline was 8.8±1.4% at lumbar spine (P<0.01), 7.3±1.1% at femoral neck 
(P<0.01), 7.9±1.9% at the trochanter (P<0.01), 8.4% ±1.8% for total femur (P<0.01), and 6.9±1.1% for total body (P<0.01). 
The relative risk of vertebral fractures in the clodronate group vs. controls was 0.63 (CI: 0.35-0.98).
vehmanen et al., 200446 Breast cancer
45
a) i.v. clodronate 1500 mg once monthly for 9 months
B) Untreated controls
The mean bone loss in the lumbar spine at 6 months was -0.5% in the clodronate group and -1.4% in the control group (P=0.22) 
and, at 12 months, -3.9% and -3.6%, respectively in the two groups (P=0.62).
abitbol et al., 200547 Prevention of GiOP in iBd
67
a) i.v. clodronate 300 mg once monthly for 3 months
B) i.v. placebo once monthly for 3 months
At 1 year, there was no change in mean BMD in the clodronate group, neither at the spine (-0.2%, NS) nor at the femoral neck 
(2.3%, NS). In contrast, there was a significant decrease in mean BMD at both lumbar spine (-2.0%, P=0.0018) and femoral 
neck (-1.7%, P=0.045) in the placebo group.
rodrigues et al., 200748 adT
94
a) i.v. clodronate 1500 mg every month for 36 months
B) i.v. zoledronate 4 mg every month for 36 months
c) i.v. placebo every month for 36 months
At the end of the 36-month study period, the untreated group had a mean BMD loss (T score) of -1.82±0.94, with 13 cases of 
osteopenia and 18 cases of osteoporosis. The clodronate group had 28 cases of osteopenia and 7 cases of osteoporosis at 36 
months, with a mean BMD loss of -0.72±0.34. The zoledronate arm had 20 and 5 cases of osteopenia and osteoporosis at month 
36, respectively, with a mean bone loss of -0.88±0.32.
Saarto et al., 200849 
(extended follow-up of38)
Breast cancer
268
A) Oral clodronate 1600 mg daily for 3 years (plus antiestrogens)
B) Untreated controls (antiestrogens only)
During the 10-year period, 14 patients developed spinal osteoporosis (3/41 in the clodronate group, and 11/48 in the control 
group), and 14/89 patients were diagnosed with hip osteoporosis (7/41 in the clodronate group, and 7/48 in the control 
group). The 10-year spinal, osteoporosis-free survival rate was 92.7% in the clodronate group and 77.0% in the control group 
(P=0.035). No difference was seen in the frequency of hip osteoporosis (85.4% vs. 82.9%; P=0.92).
Tauchmanova et al., 200950 ScS and OP/osteopenia
46
A) i.m. clodronate 100 mg weekly for 12 months (plus calcium/
vitamin d)
B) calcium/vitamin d only
After 12 months of treatment, a significant increase in lumbar BMD occurred in the clodronate group (P=0.04), while bone 
turnover markers decreased by about one third (P<0.05). In the control group, bone turnover markers did not change and 
mean BMD slightly decreased (P=NS). The differences between groups in bone turnover markers and in lumbar BMD were 
significant (P<0.05). No new vertebral fracture occurred in the clodronate group, while the spine radiographies revealed 2 new 
fractures and a worsening of 2 pre-existent fractures in controls. an improvement in vaS back pain score was observed in the 
clodronate group (from 4.3±2.7 to 2.9±2.0; P<0.05) but not in controls (from 4.4±3.1 to 4.2±3.4; P=NS).
Mccloskey et al., 201051 Breast cancer
851
C) Oral clodronate 1600 mg daily for 2 years (plus antiestrogens)
d) Placebo daily for 2 years
After 2 years, spine BMD was 1.92% higher in patients who received clodronate compared to placebo (P<0.0001) and total 
hip BMD was 1.29% higher (P=0.002 vs. placebo). Patients who received clodronate had a median 26% reduction in levels of 
serum PINP after 2 years of therapy, compared to an increase in patients on placebo (P<0.0001). Early changes in PINP were 
associated with changes in BMd and the likelihood of developing bone metastases.
BMD: bone mineral density; GIOP: glucocosrticoid-induced osteoporosis; i.m.: intramuscular; FP: fluticasone propionate: BDP: 
beclomethasone dipropionate; HPN: home parenteral nutrition; i.v.: intravenous; RA: rheumatoid arthritis; CI: confidence interval; IBD: 
inflammatory bowel disease; NS: not significant; ADT: androgen deprivation therapy; SCS: subclinical Cushing syndrome; OP: osteoporosis; 
vaS: visual analogue Scale; PinP: n-terminal pro-peptide of type i procollagen.
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Table II.—Results of studies with clodronate in the treatment of secondary osteoporosis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
rizzoli et al., 199637 Breast cancer
67
a) Oral clodronate 1600 mg daily for 9 months
B) Untreated controls
BMd at lumbar spine, femoral neck and midfemoral shaft slightly increased in the clodronate group, compared to small 
decreases in controls. In 15 women without evident lumbar spine bone metastasis (7 clodronate-treated and 8 controls), 
mean lumbar spine BMD increased vs. baseline in the clodronate group by +5.2±2.5% vs. -0.3±1.4%, and +8.1±4.7% vs. 
-0.9±1.7%, after 10.3±0.4 and 17.3±1.2 months, respectively (P<0.01). The rate of bone complications (pathological fracture, 
hypercalcemic episode, scintigraphic or radiological evidence of metastasis development, chemo- or radiotherapy for bone 
disease progression) was 28.8 events/100 patient/year in the clodronate group vs. 39.0 in controls, and 31.5 vs. 40.5, after 9 and 
15 months of follow-up, respectively.
Saarto et al., 199738 Breast cancer
121
A) Oral clodronate 1600 mg daily for 3 years (plus antiestrogens)
B) Untreated controls (antiestrogens only)
at 2 years, clodronate with antiestrogens markedly increased BMd in the lumbar spine and femoral neck by 2.9% and 3.7% 
(P=0.001 and P=0.006 respectively). There were no significant changes in BMD in the patients given antiestrogens only.
Saarto et al., 199739 Breast cancer
148
A) Oral clodronate 1600 mg daily for 2 years (plus chemotherapy)
B) Untreated controls (chemotherapy only)
Mean changes in BMd at lumbar spine and femoral neck were -5.9% and -2.0% without clodronate and -2.2% and +0.9% with 
clodronate at 2 years (P=0.0005 and 0.017, respectively). Patients who developed amenorrhea after chemotherapy had a rapid 
bone loss, which was significantly reduced by clodronate. In controls, bone loss was 9.5% at the lumbar spine and 4.6% at the 
femoral neck, while in the clodronate group, bone loss was 5.9% and 0.4%, respectively, at 2 years.
Herrala et al., 199840 GiOP in asthma
74
a) Oral clodronate 800 mg daily for 12 months
B) Oral clodronate 1600 mg daily for 12 months
c) Oral clodronate 2400 mg daily for 12 months
d) Placebo daily for 12 months
Mean BMD at lumbar spine increased significantly from baseline to month 12 in the clodronate groups of 1600 and 2400 mg/
day, i.e. 2.6% (P<0.02) and 3.0% (P<0.01), respectively, but not in the placebo and clodronate 800 mg/day groups. The test for 
a linear dose trend (lumbar spine BMD percent change) at 12 months was significant (P<0.02). The mean BMD at femoral neck 
increased significantly in the 2400 mg/day group, i.e. (4.3%, P<0.0001), as well as in the trochanter region (2.8%, P<0.02).
Muratore et al., 200041 GiOP in asthma
60
A) i.m. clodronate 100 mg every two weeks for one year (plus 
inhaled FP and oral calcium)
B) i.m. clodronate 100 mg every two weeks for one year (plus 
inhaled BdP and oral calcium)
C) Untreated controls (only inhaled FP and oral calcium)
D) Untreated controls (only inhaled BDP and oral calcium)
Mean BMD at lumbar level significantly increased from baseline to month 12 in the groups receiving clodronate and 
significantly decrease in groups not receiving clodronate. A statistically significant increase in mean BMD at month 12 was 
observed in groups a and B compared to groups c and d, respectively.
Saarto et al., 200142 
(follow-up of38)
Breast cancer
61
A) Oral clodronate 1600 mg daily for 3 years (plus antiestrogens)
B) Untreated controls (antiestrogens only)
Al 3 years, clodronate slightly increased BMD at lumbar spine (+1.0% vs. -1.7% in controls, P=0.01) and at femoral neck 
(+2.4% vs. -0.4%, P=0.12). at 5 years of follow-up, 2 years after the end of therapy, clodronate vs. controls was -1.0% vs. 
-3.2% (P=0.06) at lumbar spine and -0.1% vs. -5.2% (P=0.001) at femoral neck.
vehmanen et al., 200143 
(follow-up of39)
Breast cancer
73
A) Oral clodronate 1600 mg daily for 3 years (plus chemotherapy)
B) Untreated controls (chemotherapy only)
Clodronate significantly reduced the bone loss in the lumbar spine (-3.0%) compared with controls (-7.4%) at three years 
(P=0.003), but no significant difference was found in the femoral neck (-1.7% vs. -2.8%, P=0.86). These differences were still 
seen at 5 years: -5.8% vs. -9.7% at lumbar spine (P=0.008) and -3.5% vs. -5.1% at femoral neck (P=0.91).
Haderslev et al., 200244 HPn
20
a) i.v. clodronate 1500 mg every three months for one year
B) i.v. placebo every three months for one year
The mean BMD at lumbar spine increased by 0.8%±2.0% in the clodronate group and decreased by 1.6%±2.0% in the placebo 
group (P=0.43 between groups). At all secondary skeletal sites (hip, total body and distal forearm), there were small increases 
in the BMd in the clodronate group and decreases in the placebo group. Biochemical markers of bone resorption decreased 
significantly in the clodronate group (P<0.05).
Frediani et al., 200345 Prevention of GiOP in ra
163
A) i.m. clodronate 100 mg weekly for 48 months (plus calcium/
vitamin d)
B) calcium/vitamin d only
BMD did not change significantly in the clodronate group and declined significantly in control group. The difference between 
groups at 48 months in mean changes from baseline was 8.8±1.4% at lumbar spine (P<0.01), 7.3±1.1% at femoral neck 
(P<0.01), 7.9±1.9% at the trochanter (P<0.01), 8.4% ±1.8% for total femur (P<0.01), and 6.9±1.1% for total body (P<0.01). 
The relative risk of vertebral fractures in the clodronate group vs. controls was 0.63 (CI: 0.35-0.98).
vehmanen et al., 200446 Breast cancer
45
a) i.v. clodronate 1500 mg once monthly for 9 months
B) Untreated controls
The mean bone loss in the lumbar spine at 6 months was -0.5% in the clodronate group and -1.4% in the control group (P=0.22) 
and, at 12 months, -3.9% and -3.6%, respectively in the two groups (P=0.62).
abitbol et al., 200547 Prevention of GiOP in iBd
67
a) i.v. clodronate 300 mg once monthly for 3 months
B) i.v. placebo once monthly for 3 months
At 1 year, there was no change in mean BMD in the clodronate group, neither at the spine (-0.2%, NS) nor at the femoral neck 
(2.3%, NS). In contrast, there was a significant decrease in mean BMD at both lumbar spine (-2.0%, P=0.0018) and femoral 
neck (-1.7%, P=0.045) in the placebo group.
rodrigues et al., 200748 adT
94
a) i.v. clodronate 1500 mg every month for 36 months
B) i.v. zoledronate 4 mg every month for 36 months
c) i.v. placebo every month for 36 months
At the end of the 36-month study period, the untreated group had a mean BMD loss (T score) of -1.82±0.94, with 13 cases of 
osteopenia and 18 cases of osteoporosis. The clodronate group had 28 cases of osteopenia and 7 cases of osteoporosis at 36 
months, with a mean BMD loss of -0.72±0.34. The zoledronate arm had 20 and 5 cases of osteopenia and osteoporosis at month 
36, respectively, with a mean bone loss of -0.88±0.32.
Saarto et al., 200849 
(extended follow-up of38)
Breast cancer
268
A) Oral clodronate 1600 mg daily for 3 years (plus antiestrogens)
B) Untreated controls (antiestrogens only)
During the 10-year period, 14 patients developed spinal osteoporosis (3/41 in the clodronate group, and 11/48 in the control 
group), and 14/89 patients were diagnosed with hip osteoporosis (7/41 in the clodronate group, and 7/48 in the control 
group). The 10-year spinal, osteoporosis-free survival rate was 92.7% in the clodronate group and 77.0% in the control group 
(P=0.035). No difference was seen in the frequency of hip osteoporosis (85.4% vs. 82.9%; P=0.92).
Tauchmanova et al., 200950 ScS and OP/osteopenia
46
A) i.m. clodronate 100 mg weekly for 12 months (plus calcium/
vitamin d)
B) calcium/vitamin d only
After 12 months of treatment, a significant increase in lumbar BMD occurred in the clodronate group (P=0.04), while bone 
turnover markers decreased by about one third (P<0.05). In the control group, bone turnover markers did not change and 
mean BMD slightly decreased (P=NS). The differences between groups in bone turnover markers and in lumbar BMD were 
significant (P<0.05). No new vertebral fracture occurred in the clodronate group, while the spine radiographies revealed 2 new 
fractures and a worsening of 2 pre-existent fractures in controls. an improvement in vaS back pain score was observed in the 
clodronate group (from 4.3±2.7 to 2.9±2.0; P<0.05) but not in controls (from 4.4±3.1 to 4.2±3.4; P=NS).
Mccloskey et al., 201051 Breast cancer
851
C) Oral clodronate 1600 mg daily for 2 years (plus antiestrogens)
d) Placebo daily for 2 years
After 2 years, spine BMD was 1.92% higher in patients who received clodronate compared to placebo (P<0.0001) and total 
hip BMD was 1.29% higher (P=0.002 vs. placebo). Patients who received clodronate had a median 26% reduction in levels of 
serum PINP after 2 years of therapy, compared to an increase in patients on placebo (P<0.0001). Early changes in PINP were 
associated with changes in BMd and the likelihood of developing bone metastases.
BMD: bone mineral density; GIOP: glucocosrticoid-induced osteoporosis; i.m.: intramuscular; FP: fluticasone propionate: BDP: 
beclomethasone dipropionate; HPN: home parenteral nutrition; i.v.: intravenous; RA: rheumatoid arthritis; CI: confidence interval; IBD: 
inflammatory bowel disease; NS: not significant; ADT: androgen deprivation therapy; SCS: subclinical Cushing syndrome; OP: osteoporosis; 
vaS: visual analogue Scale; PinP: n-terminal pro-peptide of type i procollagen.
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these trials, the dosing regimen of oral clodro-
nate used was greater (1600 mg/day) compared 
to that usually prescribed for the management of 
postmenopausal osteoporosis (800 mg/day), be-
ing doubled. in an earliest trial,37 67 women with 
relapsing breast cancer were treated with oral 
clodronate 1600 mg/day for 8 months or acted as 
untreated controls. Treatment with clodronate in-
creased BMd at lumbar spine and other skeletal 
sites, compared to decreases in the control group, 
and was associated with more marked increases 
of BMd in woman without evident lumbar spine 
bone metastases.
When given in addition to antiestrogen therapy 
in patients with early stage breast cancer oral clo-
dronate 1.6 g/day significantly increased BMD 
in the lumbar spine and femoral neck, compared 
to no significant changes in BMD in the control 
group of patients given anti-oestrogens only.38 at 
the follow-up at 3 and 5 years,42 clodronate was 
confirmed to be able to retard, but not to totally 
prevent, the bone loss related to the withdrawal of 
hormone replacement therapy, especially in lum-
bar spine. in the extended 10-years follow-up in 
268 patients,49 3 of 41 patients in the clodronate 
group, and 11 of 48 in the control group, devel-
oped spinal osteoporosis, with similar rates with 
hip osteoporosis. The 10-year spinal osteoporo-
sis-free survival rate was significantly higher in 
the clodronate group than in the control group.
in another study39 with oral clodronate 1.6 g/
day given in addition to chemotherapy in 148 
premenopausal women with primary breast 
cancer and absence of skeletal metastases treat-
ment with clodronate significantly reduced bone 
loss at 2 years caused by chemotherapy-induced 
ovarian failure. in the follow-up at 3 and 5 years, 
i.e. 2 years after the end of therapy,43 the bone 
loss was still significantly less in the clodronate 
group compared with the control group receiving 
chemotherapy only.
in a subgroup analysis of a large, placebo-con-
trolled study in 851 women with primary breast 
cancer,51 clodronate 1600 mg/day for 2 years was 
associated with increased BMd at lumbar spine 
and total hip, with reduced bone turnover and 
protection against bone metastases, compared to 
placebo. effects on BMd persisted for up to 3 
years post-treatment.
poorly to BPs commonly used to treat osteopo-
rosis, especially when they are used at the dosing 
regimens approved. This issue has been clearly 
demonstrated in randomized-controlled trials 
with zoledronic acid in patients presenting with 
thalassemia-associated osteoporosis, in which 
higher dosing regimens were used to achieve 
significant effects on the bone mineral density. 
Unfortunately, the safety of these dosing regi-
ments has not been established. in this context, 
clodronate demonstrated to maintain the BMd, 
reduce the bone turnover markers and improve 
bone pain in patients presenting with thalassemia 
and low bone mass, with a good profile of safety 
and tolerability.54 These findings were not con-
firmed in another study55 that has evaluated the 
effects of long-term cyclical clodronate therapy 
(300 mg i.v. every 3 weeks for 2 years) and of an 
active placebo (calcium and vitamin D) on bone 
mass and bone turnover in 30 male patients with 
beta-thalassemia major, in which no increases in 
areal bone density were observed.
Effects of clodronate in neoplastic diseases
in recent years, the role of BPs in the manage-
ment of neoplastic diseases has expanded. The 
rationale for use of antiresoptive therapies in 
oncology is based on their effects in preventing 
complications related to bone metastases in dif-
ferent types of cancer (mainly breast and prostate 
cancer), their inhibitory action on osteolysis that 
can limit bone marrow invasion and the survival 
of any inactive cancer cells in the micro-environ-
ment of the bone marrow, and their inhibitory 
action on osteopenia and osteoporosis caused by 
anti-neoplastic hormones and chemotherapies. 
Several trials have shown that BPs reduces the 
risk of skeletal events and delay the time to skel-
etal events, and may also reduce bone pain and 
improve quality of life in patients with metastatic 
breast cancer or other types of cancer.56 in most 
of these trials authors evaluated, as a second-
ary endpoints, the positive effects of BPs on the 
BMd and markers of bone turnover, demonstrat-
ing that BPs may be useful in preventing “can-
cer-treatment induced bone loss” (CTIBL).
in this context, the role of oral clodronate in 
the management/prevention of cTiBL has been 
well established. it is interesting to note that, in 
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associated with characteristic Mri appearances, 
in the absence of specific signs of avascular ne-
crosis, antecedent trauma or infection.59
The classification of BME is based on the pres-
ence or absence of risk factors. Primary BMe 
is diagnosed without an identifiable underlying 
cause, whereas secondary BMe syndrome may 
be due to other conditions, such as degenerative 
or inflammatory rheumatic diseases, ischemic 
insults, infections, neoplasia, iatrogenic effects, 
metabolic diseases or neurological conditions.60
The complex regional pain syndrome (CRPS), 
a severely disabling pain syndrome characterized 
by sensory and vasomotor disturbance, edema and 
functional impairment, sometimes developing 
following a trauma or surgery, is included among 
the BMe syndromes. Typically, a single extremity 
is affected, and the syndrome may develop in the 
setting of major nerve injury (CRPS type II) or in 
the absence of such injury (CRPS type I).61 in at 
least 10% of cases, it is not possible to identify an 
event correlated with the disease. in addition to the 
typical MRI finding of BME, other possible CRPS 
radiological features are a patchy or diffuse osteo-
porosis in the painful region and the enhanced ra-
dionuclide uptake on bone scintigraphy.62
BPs are the drug class with the best profile 
of efficacy in the treatment of CRPS. Their use 
in crPS patients was originally based on their 
analgesic properties, which are well documented 
in a variety of bone and joint disorders, as well 
as in other painful situations unrelated to bone 
and joint diseases.63 The effects of BPs on pain 
may be attributable to their ability to inhibit the 
production of prostaglandins, lactic acid, and/or 
various neuropeptides and neuromodulators, all 
of which are possibly involved in the sensitiza-
tion of afferent nerve fibres and pain modula-
tion.64 in patients with crPS, BPs may also in-
terfere with the pathogenic pathway triggered by 
the mononuclear-phagocyte lineage locally acti-
vated by tissue injuries by an inhibition of pro-
liferation, activation and viability of monocytes 
and macrophages, by decreasing the production 
of TNF-α and other proinflammatory cytokines 
and by the inhibition of keratinocyte prolifera-
tion and growth.62
Over the past few decades, the results of sev-
eral clinical trials have suggested the potential 
There is less evidence of efficacy with the use 
of the i.v. route of administration of clodronate in 
women with breast cancer. in 45 premenopausal 
women with early stage breast cancer46 7 cycles 
of i.v. clodronate 1500 mg had limited effects in 
the prevention of bone loss related to chemother-
apy-induced ovarian failure.
With regard to prostate cancer, it is well es-
tablished that a rapid loss of BMd occurs within 
the first 6 to 12 months of androgen-deprivation 
therapy57 and that BPs therapy is effective in 
increasing BMd and reducing the incidence of 
pathological fractures in prostate cancer patients 
on androgen deprivation therapy.58 in a study48 
performed to evaluate the effects of androgen 
deprivation therapy in promoting osteoporosis or 
osteopenia, 94 prostatectomized men with rising 
prostate-specific antigen were randomized to re-
ceive i.v. clodronate 1500 mg every month, i.v. 
zoledronic acid 4 mg/month, or placebo, for 36 
months. a progressive bone loss was observed 
in the untreated 31 patients, who developed os-
teoporosis or osteopenia, compared with small 
decreases in BMP and fewer cases of osteopo-
rosis in patients treated with clodronate or zole-
dronate. The protective effect in BMd loss at 18 
months was significantly higher with clodronate 
than with zoledronate. This study showed that 
i.v. BPs (and particularly clodronate) have a pro-
tective effect in patients undergoing androgen 
deprivation therapy.
in conclusion, clodronate demonstrated to be 
effective in the management of several differ-
ent types of secondary osteoporosis, producing 
beneficial effects on the BMD and bone turnover, 
comparable to that reported in postmenopausal 
and elderly women in which the anti-fracture ef-
ficacy of clodronate has been established. It is 
however interesting to note that in some of these 
conditions (CTIBL) clodronate demonstrated its 
efficacy at doses superior than those commonly 
used (1600 mg/day versus 800 mg/day).
The use of clodronate in bone marrow edema 
syndromes
The bone marrow edema (BME) syndrome can 
be defined as a clinico-radiological entity in 
which transient non-specific subacute or chronic 
joint pain, predominantly of the hip and knee, is 
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that tested the efficacy of neridronate in CRPS,68 
the improvements of clinical parameters in pa-
tients treated with clodronate were comparable 
to those reported with neridronate.
The effects of clodronate and neridronate in 
the treatment of crPS were directly compared 
in another study,67 in which 18 patients with 
femoral head algodystrophy were randomized to 
receive i.v. clodronate 300 mg for 12 days or i.v. 
neridronate 100 mg given four times in 10 days. 
Efficacy was evaluated by means of a VAS for 
pain, clinical score, bone turnover markers (uri-
nary nTx/creatinine ratio, alkaline phosphatase 
and osteocalcin) and radiological findings. Both 
drugs were effective, but the improvements of 
clinical, laboratory and radiological parameters 
were more rapid in patients treated with neridro-
nate than those observed in the clodronate group.
The results of the above clinical studies indi-
cate that treatment with i.v. clodronate in patients 
with crPS is associated with clinically relevant 
and persistent benefits. However, the results of 
the comparison with neridronate suggest that a 
global dose of 3000 mg may be inadequate for 
the treatment of crPS and that, therefore, a 
higher dose may be needed to maximise clinical 
response.
Clodronate in the treatment of osteoarthritis
The real pathogenesis of Oa is still unclear and 
the question whether Oa is a disease affecting 
bone, cartilage or both, is still unanswered. There 
are data suggesting that not only cartilage is in-
beneficial effects of BPs in reducing pain and im-
proving physical function in patients with crPS-
i.65 The BPs efficacy is greater when therapy is 
started in early stages of disease and this con-
firms their ability to contrast the phlogistic pro-
cesses, which are predominant in the first phase 
of crPS.62
Table iii66, 67 summarizes the results of stud-
ies with clodronate in the treatment of BMe syn-
dromes.
in a randomized, double blind, placebo-con-
trolled study,66 32 patients with crPS-i were 
randomized to receive either i.v. clodronate 300 
mg/day for 10 consecutive days or placebo; 40 
days later, the placebo treated patients received 
the clodronate treatment. The evaluation of ef-
ficacy was based on a visual analogue scale of 
pain (VAS, range 0-100), the clinical global 
assessment (CGA, range 0-3) and an efficacy 
verbal score (EVS, range 0-3). Clinical and bio-
chemical assessments were performed before the 
treatment, 40, 90 and 180 days later. Forty days 
after treatment, subjects receiving clodronate 
showed significantly improved VAS, CGA and 
EVS score compared with controls (P<0.001 be-
tween groups in all parameters). These improve-
ments were further sustained after 180 days from 
the start of treatment. When clodronate infusions 
were administered to patients who had previous-
ly received placebo, significant differences ad 
day 40 were observed in comparison with values 
measured 40 days of treatment with placebo. in 
comparisons with the results obtained in a ran-
domized, double-blind placebo-controlled study 
Table III.—Results of studies with clodronate in bone marrow edema syndromes.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
varenna et al., 200066 crPS-i
32
a) i.v. clodronate 300 mg daily for 10 days
B) i.v. placebo daily for 10 days, then (at day 40) clodronate 300 mg daily for 
10 days
At 40 days from the start of treatment, patients randomized to clodronate had significant decreases of pain VAS and CGA 
(P=0.002 and P=0.001, respectively). Compared with the placebo group, significant differences were found in all clinical 
variables (VAS: P=0.001; CGA: P=0.001; EVS.: P<0.0001). When clodronate was given to patients who received placebo in 
the double blind phase, all variables significantly improved compared to values measured after 40 days with placebo. Pooling 
the results of all 32 patients after clodronate treatment, at day 180 the overall percentage decrease of VAS was 93.2%±15.6%, 
with 30 patients significantly improved or asymptomatic.
Muratore et al. 200467 Femoral head 
algodystrophy
18
a) i.v. clodronate 300 mg daily for 12 days
B) i.v. neridronate 100 mg in 4 administrations over 10 days
in both treatment groups, nTX, alkaline phosphatase and osteocalcin levels at 30 days of treatment were indicative of the 
reduction of bone turnover; however, in the neridronate group changes from baseline were statistically significant from Day 
15. although the radiological assessment showed a decrease of bone rarefaction in both groups, complete healing of femoral 
head was significantly more marked in patients treated with neridronate than in those treated with clodronate. Pain decrease and 
functional recovery were observed in both groups, more markedly in the neridronate group.
crPS-i: complex regional pain syndrome type i; i.v.: intravenous; vaS: visual analogue Scale; cGa: clinical global assessment; evS: 
efficacy verbal score; NTX: N-terminal telopeptide.
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ty of clodronate in the treatment of hand and 
knee OA (Table IV).71-75 Two published articles 
have shown that clodronate is effective for pain-
ful erosive OA of the hands. In the first one,74 
29 patients were treated with i.v. clodronate 300 
mg for 7 days. Treatment was repeated every 3 
months for a total number of 73 cycles, and was 
associated with a significant reduction in pain 
measured with VAS score (P=0.0001). Clodro-
nate also determined an increase of strength of 
the hands and a significant decrease from base-
line in the number of painful joints.
in the second study,72 24 patients were treated 
with i.v. clodronate 300 mg for 7 days as attack 
dose, followed by i.m. clodronate 100 mg for 14 
days every three months and by a 24-month fol-
low-up. a control group of 14 patients received 
hydroxyl-chloroquine 400 mg daily for 30 days, 
followed by 200 mg daily for the next 11 months. 
Treatment with clodronate was associated with 
a significant reduction in pain (P<0.001), Drei-
ser score (P=0.012) and number of tender joints 
(P=0.0011), as well as with significant im-
provements of strength of right (P=0.04) and 
left (P=0.016) hands, physician’s global assess-
ment (P<0.001) and patient’s global assessment 
(P=0.021). Treatment with hydroxyl-chloroquine 
was ineffective and of poor patients’ acceptance.
Other 3 studies have shown that intraarticular 
(i.a.) clodronate is effective in the management 
of knee Oa. The effects of 6 i.a. injections of 
clodronate 0.9 mg on pain and synovial fluid 
concentration of inflammatory mediators were 
evaluated in 20 patients with synovitis secondary 
volved in the development of Oa, as the sub-
chondral bone seems to play a crucial role in the 
pathogenesis of the disease. These data represent 
a very important change in the study of Oa as 
originally it was proposed that Oa was protec-
tive for osteoporosis and viceversa.69
The role of BPs in the management and in the 
prevention of Oa is still under debate. BPs are 
commonly used as antiosteoporotic drugs be-
cause of their ability to inhibit bone resorption, 
and this could be the rationale for its use. There 
are papers showing that in surgical and animal 
models BPs are able to protect bone and carti-
lage from pathological changes. in clinical set-
ting risedronate showed positive effects on joint 
structure in Oa, but there are no data showing 
the ability of BPs to slow the progression of the 
disease.69
a recent meta-analysis70 that has examined 
the results of 13 studies including 3823 partici-
pants in order to evaluate the effects of BPs in 
the treatment of OA pain (8 studies in OA of the 
knee, 1 of the hand, 3 of the spine and 1 of the 
hip), concluded that there is limited evidence that 
BPs are effective in the treatment of Oa pain. in 
particular, two of these studies involving more 
than 2000 patients with knee Oa were not able 
to demonstrate the efficacy of risedronate on the 
Oa pain. However, only two studies with clodro-
nate were included in the meta-analysis71, 72 and 
both of them were indicative of positive effects 
of clodronate in Oa pain.
The search in literature has found 5 published 
papers that have evaluated the efficacy and safe-
Table III.—Results of studies with clodronate in bone marrow edema syndromes.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
varenna et al., 200066 crPS-i
32
a) i.v. clodronate 300 mg daily for 10 days
B) i.v. placebo daily for 10 days, then (at day 40) clodronate 300 mg daily for 
10 days
At 40 days from the start of treatment, patients randomized to clodronate had significant decreases of pain VAS and CGA 
(P=0.002 and P=0.001, respectively). Compared with the placebo group, significant differences were found in all clinical 
variables (VAS: P=0.001; CGA: P=0.001; EVS.: P<0.0001). When clodronate was given to patients who received placebo in 
the double blind phase, all variables significantly improved compared to values measured after 40 days with placebo. Pooling 
the results of all 32 patients after clodronate treatment, at day 180 the overall percentage decrease of VAS was 93.2%±15.6%, 
with 30 patients significantly improved or asymptomatic.
Muratore et al. 200467 Femoral head 
algodystrophy
18
a) i.v. clodronate 300 mg daily for 12 days
B) i.v. neridronate 100 mg in 4 administrations over 10 days
in both treatment groups, nTX, alkaline phosphatase and osteocalcin levels at 30 days of treatment were indicative of the 
reduction of bone turnover; however, in the neridronate group changes from baseline were statistically significant from Day 
15. although the radiological assessment showed a decrease of bone rarefaction in both groups, complete healing of femoral 
head was significantly more marked in patients treated with neridronate than in those treated with clodronate. Pain decrease and 
functional recovery were observed in both groups, more markedly in the neridronate group.
crPS-i: complex regional pain syndrome type i; i.v.: intravenous; vaS: visual analogue Scale; cGa: clinical global assessment; evS: 
efficacy verbal score; NTX: N-terminal telopeptide.
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Western Ontario MacMaster (WOMAC) pain 
subscale, global knee Oa evaluation from both 
patients and investigators significantly improved 
in the clodronate group. Finally the acetamino-
phen consumption decreased in patients treated 
with clodronate (P<0.05) compared to placebo.
a recent paper13 has shown that in-vitro clo-
dronate exerts an anabolic effect on articular 
chondrocytes mediated through the purinergic 
receptor pathway. in particular, clodronate is 
able to produce in the cartilage an increasing ac-
cumulation of ecM by 90% after 4 weeks of cul-
ture and without an associated effect on matrix 
turn-over. The findings support the previous clin-
ical evidence and suggest that clodronate may be 
useful as adjunctive therapies to potentially ame-
liorate progression of cartilage degeneration and 
improve the management of Oa.
The use of clodronate in orthopedic surgery
clodronate is largely used in the treatment of 
fracturative complications of osteoporosis that 
are treated surgically (osteosynthesis or pros-
thetic replacement) or not-invasively (reduction-
contention in external tutorials). In the field of 
to knee Oa.73 Treatment with clodronate led to 
a significant reduction in spontaneous pain and 
pain on active movement (P<0.05), which was 
correlated with the clodronate-induced reduction 
in prostaglandin e2 levels.
in another study,71 145 patients with knee Oa 
were divided in 5 groups and were treated with 
i.a. clodronate at different doses (0.5 mg/week 
for 4 weeks, 1 mg/week for 4 weeks, 2 mg/week 
for 4 weeks, 1+1 mg/week for 2 weeks) or with 
i.a. hyaluronic acid 20 mg/week for 4 weeks. in 
this study, weekly i.a. clodronate was at least 
as effective as hyaluronic acid in symptomatic 
and functional improvements of knee Oa, as 
measured by means of a vaS for pain and the 
Lequesne index. in patients treated with clo-
dronate, a significant (P=0.03) linear trend for a 
dose-response relationship was found for active 
movement vaS pain.
in the third study,75 80 patients with knee 
Oa were treated with weekly i.a. clodronate 2 
mg or matched placebo for 4 weeks, followed 
by 12 weeks of follow-up. Five weeks after the 
last injection, a significant reduction in pain was 
observed in the clodronate group compared to 
placebo (P<0.05). Moreover, Lequesne Index, 
Table IV.—Results of studies with clodronate in the treatment of osteoarthritis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
cocco et al., 199973 Oa of the knee
20
i.a. clodronate 0.9 mg on day 1, 3, 7, 10, 14 and 21 Statistically significant reductions (P<0.05) of spontaneous pain and pain on active movement, evaluated by a 100-mm VAS, 
were observed at end of treatment. The decrease of pain was correlated with the clodronate-induced reduction of prostaglandin 
e2 levels.
Saviola et al., 200074 Oa of the hand
29
i.v. clodronate 300 mg every 3 months (73 cycles in total) Mean VAS for pain decreased from 5.63±2.14 to 2.93±1.95 (P=0.0001); the pain reduction lasted for a mean of 88.33 days. 
Strength of the hands (mmHg) was measured in 16/73 cycles and increased on the right from 169.38±75.85 to 190.31±81.76, 
and on the left from 180.56±68.27 to 196.11±85.55 (P=NS). The number of painful joints decreased from 4.75±2.52 to 
2.56±1.93 (P=0.0011), and the number of swollen joints decreased from 3.07±2.69 to 2.67±2.61 (P=NS).
rossini et al., 200971 Oa of the knee
145
a) i.a. clodronate 0.5 mg weekly for 4 weeks
B) i.a. clodronate 1 mg weekly for 4 weeks
c) i.a. clodronate 2 mg weekly for 4 weeks
d) i.a. clodronate 1 mg two injections/week for 2 weeks
e) Hyaluronic acid 20 mg weekly for 4 weeks
VAS for different types of pain and the Lequesne index significantly improved in all treatment groups after the first injection 
and continued to improve even 2-4 weeks after the last injection without significant difference among the groups. A significant 
(P=0.03) linear trend for a dose-response (0.5-2 mg clodronate) relationship was found for active movement VAS pain. 
Both joint extension and mobility scores improved significantly at all time points in all treatment groups without statistical 
differences among them.
Saviola et al., 201272 Oa of the hand
38
a) i.v. clodronate 300 mg for 7 days, followed by i.m. clodronate 100 mg/day 
for 14 days every 3 months, for a total of 24 months
B) Hydroxychloroquine 400 mg daily for 30 days, followed by 200 mg daily 
for the next 11 months
Patients in group A had significant improvements in pain reduction (P<0.001), Dreiser’s score (P=0.012), number of tender 
joints (P=0.011), strength of right (P=0.04) and left (P=0.016) hands, physician’s global assessment (P=0.001), and patient’s 
global assessment (P=0.021). In group B, 8/14 hydroxychloroquine was ineffective and enrolment was stopped.
rossini et al., 201575 Oa of the knee a) i.a. clodronate 2 mg weekly for 4 weeks
B) i.a. placebo weekly for 4 weeks
A significant difference in favour to clodronate in VAS for pain was observed 5 weeks after the last injection (-114.6 vs. -87.2 
for clodronate and placebo group, respectively; P<0.05). The improvements in Lequesne index, global knee OA evaluation 
from both patients and investigators, and the WOMAC pain subscale were significantly greater in the clodronate group. The 
proportion of patients that did not require acetaminophen was significantly greater in the clodronate group (about 10 vs. 30% 
for clodronate and placebo group, respectively; P<0.05).
OA: osteoarthritis; i.a.: intraarticular; VAS: visual analogue scale; i.v.: intravenous; NS: not significant; i.m.: intramuscular; WOMAC: 
Western Ontario MacMaster.
Th
is 
do
cu
m
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
at
io
na
l c
op
yr
ig
ht
 la
ws
. N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
 It
 is
 p
er
m
itt
ed
 fo
r p
er
so
na
l u
se
 to
 d
ow
nl
oa
d 
an
d 
sa
ve
 o
nl
y 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
. I
t i
s 
no
t p
er
m
itt
ed
 to
 m
ak
e 
ad
di
tio
na
l c
op
ie
s 
(e
ith
er
 s
po
ra
di
ca
lly
 
or
 s
ys
te
m
at
ica
lly
, e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c)
 o
f t
he
 A
rti
cle
 fo
r a
ny
 p
ur
po
se
. I
t i
s 
no
t p
er
m
itt
ed
 to
 d
ist
rib
ut
e 
th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cle
 th
ro
ug
h 
on
lin
e 
in
te
rn
et
 a
nd
/o
r i
nt
ra
ne
t fi
le
 s
ha
rin
g 
sy
st
em
s,
 e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
 m
ea
ns
 w
hi
ch
 m
ay
 a
llo
w 
ac
ce
ss
 
to
 th
e 
Ar
tic
le
. T
he
 u
se
 o
f a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cle
 fo
r a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
. T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e 
wo
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
. T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r p
er
so
na
l o
r c
om
m
er
cia
l u
se
 is
 n
ot
 p
er
m
itt
ed
. I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r, 
 o
ve
rla
y, 
ob
sc
ur
e,
 b
lo
ck
, o
r 
ch
an
ge
 a
ny
 c
op
yr
ig
ht
 n
ot
ice
s 
or
 te
rm
s 
of
 u
se
 w
hi
ch
 th
e 
Pu
bl
ish
er
 m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
. I
t i
s 
no
t p
er
m
itt
ed
 to
 fr
am
e 
or
 u
se
 fr
am
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
ad
em
ar
k,
 lo
go
, o
r 
ot
he
r 
pr
op
rie
ta
ry
 in
fo
rm
at
io
n 
of
 th
e 
Pu
bl
ish
er
.
cLOdrOnaTe in THe ManaGeMenT OF diFFerenT MUScULOSKeLeTaL cOndiTiOnS Frediani
vol. 109 - no. 4 Minerva Medica 317
the anabolic recovery, as demonstrated in experi-
mental models and in clinical trials.79
In vitro studies in ovariectomized rats80 have 
demonstrated that pre-surgery treatment with 
BPs increases the BMd of the cancellous bone 
and the stability of hydroxyapatite-coated im-
plants. in the dog model, the early administra-
tion of BPs had no significant influence on the 
extent of bone apposition, the extent or thickness 
of the hydroxyapatite coating, or the cortical or 
trabecular bone area around the implants.81
Several clinical trials have documented the 
use of BPs in the postimplant phase to prevent 
the BMd loss and to enhance the osteogenesis 
around the prosthesis components. a meta-
analysis of 6 randomized controlled trials82 sug-
gested that BPs have a beneficial effect in main-
taining periprosthetic BMd, while another me-
ta-analysis based on 14 randomized controlled 
trials83 has shown that the protective effect of 
BPs could persist up to 70 months after surgery 
and after drug discontinuation. The prevention 
of femoral periprosthetic bone loss following 
total hip arthroplasty achieved by postopera-
tive antiresorptive treatment with BPs has been 
documented up to six years of follow-up.84 in 
orthopedic surgery, clodronate may be indicated 
in subjects undergoing prosthesis surgery, either 
in the management of the peri-prosthetic osteo-
genesis, starting from the pre-operative phase 
and the immediate post-surgery, or in the treat-
ment of osteolysis in case of aseptic loosening 
due to wear debris disease.
as a consequence of the reparative osteo-
genesis (i.e. the bone growth and periprosthetic 
bone remodeling) that follows the damage of 
the cartilage-bone interface and the bone remod-
eling, a decrease in BMD in the first 3 months 
postsurgery is a common finding in joints that 
are subject to prosthesis implant. it has been 
shown76 that the loss of BMd after total hip re-
placement is not paralleled by similar decreases 
in other body regions (lumbar spine, radius, con-
tralateral hip). The loss in BMd is of mechanical 
origin and correlated with the stress-shielding 
phenomena.77 it may vary between 3% and more 
than 15%, and is generally recovered within 24 
months.78
Treatment with antiresoptive agents may 
counteract the underlying osteometabolic dam-
age, may attenuate the periprosthetic loss due to 
stress-shielding and ultimately may contribute to 
Table IV.—Results of studies with clodronate in the treatment of osteoarthritis.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
cocco et al., 199973 Oa of the knee
20
i.a. clodronate 0.9 mg on day 1, 3, 7, 10, 14 and 21 Statistically significant reductions (P<0.05) of spontaneous pain and pain on active movement, evaluated by a 100-mm VAS, 
were observed at end of treatment. The decrease of pain was correlated with the clodronate-induced reduction of prostaglandin 
e2 levels.
Saviola et al., 200074 Oa of the hand
29
i.v. clodronate 300 mg every 3 months (73 cycles in total) Mean VAS for pain decreased from 5.63±2.14 to 2.93±1.95 (P=0.0001); the pain reduction lasted for a mean of 88.33 days. 
Strength of the hands (mmHg) was measured in 16/73 cycles and increased on the right from 169.38±75.85 to 190.31±81.76, 
and on the left from 180.56±68.27 to 196.11±85.55 (P=NS). The number of painful joints decreased from 4.75±2.52 to 
2.56±1.93 (P=0.0011), and the number of swollen joints decreased from 3.07±2.69 to 2.67±2.61 (P=NS).
rossini et al., 200971 Oa of the knee
145
a) i.a. clodronate 0.5 mg weekly for 4 weeks
B) i.a. clodronate 1 mg weekly for 4 weeks
c) i.a. clodronate 2 mg weekly for 4 weeks
d) i.a. clodronate 1 mg two injections/week for 2 weeks
e) Hyaluronic acid 20 mg weekly for 4 weeks
VAS for different types of pain and the Lequesne index significantly improved in all treatment groups after the first injection 
and continued to improve even 2-4 weeks after the last injection without significant difference among the groups. A significant 
(P=0.03) linear trend for a dose-response (0.5-2 mg clodronate) relationship was found for active movement VAS pain. 
Both joint extension and mobility scores improved significantly at all time points in all treatment groups without statistical 
differences among them.
Saviola et al., 201272 Oa of the hand
38
a) i.v. clodronate 300 mg for 7 days, followed by i.m. clodronate 100 mg/day 
for 14 days every 3 months, for a total of 24 months
B) Hydroxychloroquine 400 mg daily for 30 days, followed by 200 mg daily 
for the next 11 months
Patients in group A had significant improvements in pain reduction (P<0.001), Dreiser’s score (P=0.012), number of tender 
joints (P=0.011), strength of right (P=0.04) and left (P=0.016) hands, physician’s global assessment (P=0.001), and patient’s 
global assessment (P=0.021). In group B, 8/14 hydroxychloroquine was ineffective and enrolment was stopped.
rossini et al., 201575 Oa of the knee a) i.a. clodronate 2 mg weekly for 4 weeks
B) i.a. placebo weekly for 4 weeks
A significant difference in favour to clodronate in VAS for pain was observed 5 weeks after the last injection (-114.6 vs. -87.2 
for clodronate and placebo group, respectively; P<0.05). The improvements in Lequesne index, global knee OA evaluation 
from both patients and investigators, and the WOMAC pain subscale were significantly greater in the clodronate group. The 
proportion of patients that did not require acetaminophen was significantly greater in the clodronate group (about 10 vs. 30% 
for clodronate and placebo group, respectively; P<0.05).
OA: osteoarthritis; i.a.: intraarticular; VAS: visual analogue scale; i.v.: intravenous; NS: not significant; i.m.: intramuscular; WOMAC: 
Western Ontario MacMaster.
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implants.88 clodronate 100 mg i.m. was given 
daily during the first week, then every week 
for 6 months and every 2 weeks for the next 6 
months. at the 1-year follow-up, treatment with 
clodronate was associated with a significant less 
decrease of BMd at the medial metaphyseal re-
gion, and at both medial and lateral diaphyseal 
regions, compared to untreated controls.
in another study,89 in which 13 patients un-
dergoing cementless total hip arthroplasty were 
treated postoperatively either with clodronate 
3600 mg i.v. in four months (a total loading 
dose of 1800 mg postoperatively infused over 
two hours on two consecutive days and then 900 
mg every 2 months after the surgery) or with 
placebo, clodronate prevented the BMd loss at 
proximal femur and the pelvis and significantly 
improved circulating levels of c-terminal telo-
peptide of type I collagen (ICTP) compared to 
placebo.
The efficacy of i.m. clodronate 100 mg/week 
given for 12 months to reduce bone loss around 
uncemented stems after total hip arthroplasty 
was demonstrated in another study that included 
91 patients.90 at the end of treatment, clodronate 
determined a significant reduction of bone loss, 
addition to their use by oral or i.m. route, the 
addition of BPs to acrylic bone cement is able 
to stimulate the periprosthetic osteogenesis by 
inhibiting the bone resorption due to osteoclas-
togenesis.85
The effects of the oral, i.m. and i.v. adminis-
tration of clodronate in orthopedic surgery have 
been tested in studies conducted in patients un-
dergoing total knee or hip arthroplasty (Table 
v).86-90 In the first of these studies,86 oral clodro-
nate 1600 mg daily, administered for 3 weeks be-
fore until 6 months after a total knee replacement 
with a cemented implant, significantly reduced 
early prosthetic migration. The results at 4 years 
in the same group of patients87 showed an almost 
statistically significant difference between the 
clodronate and the placebo groups in changes 
from baseline of maximal total point motion 
(MTMP), with the clodronate group showing 
25% less migration than placebo. From 1 to 4 
years, there was a continuous increase in rotation 
around the transverse axis in the controls, which 
differed from the clodronate group.
The effects of i.m. clodronate in the peri-
prosthetic bone remodeling were studied in 21 
patients operated with uncemented femoral hip 
Table V.—Results of studies with clodronate in orthopedic surgery.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
Hilding et al., 200086 Knee prosthesis
50
c) Oral clodronate 1600 mg daily from 3 weeks before to 6 months after surgery
d) Placebo from 3 weeks before to 6 months after surgery
Clodronate reduced prosthetic migration, as measured by MTPM, from 0.40 mm to 0.29 mm (P=0.01 vs. placebo).
Hilding et al., 200687 
(4-year follow-up of86)
Knee prosthesis
47
a) Oral clodronate 1600 mg daily from 3 weeks before to 6 months after surgery
B) Placebo from 3 weeks before to 6 months after surgery
At 4-year follow-up, the average migration (MTPM) at 4 years from the postoperative examination was 0.43±0.14 mm in 
the clodronate group and 0.58±0.33 mm in the placebo group (P=0.06 between groups). Rotation around the transverse axis 
(backward tilting) was 0.37±0.48º in the placebo group and 0.02±0.18º in the clodronate group (P=0.002 between groups). 
From 1 to 4 years, there was no difference in MTPM, but there was a continuous increase in rotation around the transverse axis 
in the controls, which differed from the clodronate group.
Massari et al., 200288 Hip arthroplasty
21
A) i.m. clodronate 100 mg daily during the first week, then every week for 6 
months and every 2 weeks for the next 6 months
B) Untreated control group
There was a significant less decrease of BMD in the clodronate group compared to controls: the differences were statistically 
significant for the medial metaphyseal region (-9.82% vs. -25% at 1 year) and for the diaphyseal regions, both medial (-7.87% 
vs. -9.35%) and lateral (-6.41% vs. -9.58%).
resch et al., 200789 Hip arthroplasty
13
A) i.v. clodronate 3600 mg in 4 months (a total loading dose of 1800 mg 
postoperatively in two consecutive days and then 900 mg every two months 
after surgery)
B) Placebo at the same regimen of clodronate
The mean change from baseline in BMd of the proximal femur and the pelvis were +0.07% and +0.03% in clodronate 
group, and -0.02% and -0.03% in the placebo group, respectively (NS between groups). Changes from baseline of ICTP and 
osteocalcin were -0.07% and -1.51% in the clodronate group, and +0.22% and +5.48% in the placebo group, respectively 
(P<0.05 between groups for ICTP and 0.05<P<0.10 for osteocalcin.
Trevisan et al., 201090 Hip arthroplasty
91
a) i.m. clodronate 100 mg weekly for 12 months
B) Untreated control group
At month 12, patients treated with clodronate had less bone loss at almost all zones, reaching statistical significance (P<0.05) 
in Gruen zones 2 and 6 (difference of 6.6 and 5.9%, respectively). The difference between groups was more marked in women 
than in men. Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMd 
changes.
MTMP: maximum total point motion; i.m.: intramuscular; BMd: bone mineral density; i.v.: intravenous; icTP: c-terminal telopeptide of 
type i collagen.
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i.m.) formulations of clodronate have not been 
associated with gastrointestinal effects. There 
are no clinically significant effects of oral clo-
dronate on hematological or biochemical indices 
of safety.27, 30
all BPs are eliminated via renal route. renal 
failure has been reported with administration 
of parenteral BPs, especially when adminis-
tered i.v. at high doses and high infusion rates, 
as reported for zoledronic acid.92 clodronate is 
not contraindicated in patients with renal failure 
and, although its safety in this special population 
should be further clarified, several data suggest 
that clodronate may be used also in patients with 
decreased renal function. However, clodronate 
should be administered with care in patients with 
renal impairment and the dose should be modi-
fied according to renal function,16 to be moni-
tored before and during treatment.
in recent years, cases of osteonecrosis of the 
jaw in patients receiving BPs therapy have been 
reported in literature, mostly in patients receiv-
ing the i.v. amino-BPs zoledronic acid and pami-
dronic acid.93 as clodronate is a nnBP with a 
different mechanism of action from that of nBPs, 
osteonecrosis of the jaw has been observed only 
rarely in patients treated with clodronate and 
with increased effects observed in the female 
population, which is at higher risk for bone loss.
The current evidence suggests that, while ap-
proaching the prosthetic surgery of a joint af-
fected by osteoarthritis, the metabolic damage of 
the iuxta-articular bone is carefully considered to 
optimize the complete treatment of osteoarthritis 
in all its components. Therefore, it is important 
that the joint is adequately prepared for the sur-
gery, which will cause an immediate postsurgi-
cal bone loss, as well as in the bone remodeling 
osteointegration process that follows the inter-
vention. The antiresorptive effect, the bone re-
modeling modulation, the anti-inflammatory and 
analgesic effects of clodronate, all are properties 
that are helpful in the management of patients 
undergoing orthopedic surgery.
Safety of clodronate
clodronate in generally well tolerated in any 
route of administration (oral, i.m., i.v. and i.a.) 
and is devoid of high-risk contraindications.91 in 
2-10% of cases, gastrointestinal symptoms such 
as nausea and dyspepsia develop and have been 
usually observed in people taking the drug orally 
and at high doses.16 However, parenteral (i.v. and 
Table V.—Results of studies with clodronate in orthopedic surgery.
reference diagnosisn. of patients Treatment groups, dose regimen and duration Results of efficacy
Hilding et al., 200086 Knee prosthesis
50
c) Oral clodronate 1600 mg daily from 3 weeks before to 6 months after surgery
d) Placebo from 3 weeks before to 6 months after surgery
Clodronate reduced prosthetic migration, as measured by MTPM, from 0.40 mm to 0.29 mm (P=0.01 vs. placebo).
Hilding et al., 200687 
(4-year follow-up of86)
Knee prosthesis
47
a) Oral clodronate 1600 mg daily from 3 weeks before to 6 months after surgery
B) Placebo from 3 weeks before to 6 months after surgery
At 4-year follow-up, the average migration (MTPM) at 4 years from the postoperative examination was 0.43±0.14 mm in 
the clodronate group and 0.58±0.33 mm in the placebo group (P=0.06 between groups). Rotation around the transverse axis 
(backward tilting) was 0.37±0.48º in the placebo group and 0.02±0.18º in the clodronate group (P=0.002 between groups). 
From 1 to 4 years, there was no difference in MTPM, but there was a continuous increase in rotation around the transverse axis 
in the controls, which differed from the clodronate group.
Massari et al., 200288 Hip arthroplasty
21
A) i.m. clodronate 100 mg daily during the first week, then every week for 6 
months and every 2 weeks for the next 6 months
B) Untreated control group
There was a significant less decrease of BMD in the clodronate group compared to controls: the differences were statistically 
significant for the medial metaphyseal region (-9.82% vs. -25% at 1 year) and for the diaphyseal regions, both medial (-7.87% 
vs. -9.35%) and lateral (-6.41% vs. -9.58%).
resch et al., 200789 Hip arthroplasty
13
A) i.v. clodronate 3600 mg in 4 months (a total loading dose of 1800 mg 
postoperatively in two consecutive days and then 900 mg every two months 
after surgery)
B) Placebo at the same regimen of clodronate
The mean change from baseline in BMd of the proximal femur and the pelvis were +0.07% and +0.03% in clodronate 
group, and -0.02% and -0.03% in the placebo group, respectively (NS between groups). Changes from baseline of ICTP and 
osteocalcin were -0.07% and -1.51% in the clodronate group, and +0.22% and +5.48% in the placebo group, respectively 
(P<0.05 between groups for ICTP and 0.05<P<0.10 for osteocalcin.
Trevisan et al., 201090 Hip arthroplasty
91
a) i.m. clodronate 100 mg weekly for 12 months
B) Untreated control group
At month 12, patients treated with clodronate had less bone loss at almost all zones, reaching statistical significance (P<0.05) 
in Gruen zones 2 and 6 (difference of 6.6 and 5.9%, respectively). The difference between groups was more marked in women 
than in men. Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMd 
changes.
MTMP: maximum total point motion; i.m.: intramuscular; BMd: bone mineral density; i.v.: intravenous; icTP: c-terminal telopeptide of 
type i collagen.
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osteoporotic patients with vertebral fractures.95 
This analgesic effects is not shared with other 
nBPs such as alendronate and risedronate, but 
has been reported with i.v. pamidronate.96 How-
ever, it should be taken into consideration that 
the anti-inflammatory and analgesic effects of 
clodronate have been observed in small num-
ber of patients studied, using different modes of 
administration in different diseases, and results 
were not always consistent between studies.2 
Therefore, further research is needed to better 
clarify the potential anti-inflammatory and anal-
gesic effects of clodronate beyond its antiresorp-
tive properties.
Moreover, recent research has shown that clo-
dronate has protective and anabolic effects on 
the cartilage that may counteract the process of 
cartilage degradation that occurs in the progres-
sion of Oa and rheumatoid arthritis.13, 15 a vari-
ety of studies have shown that clodronate may be 
beneficial in patients with other bone and joint 
diseases, such as Oas and bone marrow edema 
syndromes (e.g. cPrS). Finally, clinical trials 
have shown a promising role for clodronate in 
subjects undergoing prosthesis surgery, either 
in the preparation for the surgery or in the post-
operative bone remodeling phase.
However, the efficacy of clodronate in the OA, 
cPrS and postprosthetic surgeries has been in-
vestigated in trials that included small samples 
of patients, used different methods of assessment 
and routes of administration of clodronate, and 
generally did not include an active comparator. 
Therefore, caution should be used in the interpre-
tation of the available preliminary results, which 
should be confirmed in large active-controlled 
clinical trials using robust outcome measures.
different formulations and dose schedules of 
clodronate have been used over the years. in the 
management of postmenopausal osteoporosis, 
the efficacy of clodronate in increasing BMD 
and in reducing the risk of vertebral and non-
vertebral fractures has been largely documented 
with both the oral and the parenteral (i.v. and i.m. 
formulations), with an acceptable safety profile. 
notably, the positive effects of oral clodronate in 
cancer-induced bone loss have been observed at 
a doubling daily dose than that used in the man-
agement of postmenopausal osteoporosis.
mainly in patients who have a history of treat-
ment with an amino-BP.16, 93
Skin rashes and other allergic reactions have 
been described, albeit rarely, in patients taking 
clodronate, as it has been the case for transitory 
and usually clinically silent hypocalcemia.17
intramuscular injection of clodronic acid is as-
sociated with injection site pain or discomfort in 
some patients.23, 32, 33 a new i.m. formulation of 
clodronate containing 1% lidocaine has been re-
cently developed in italy to reduce the incidence 
and severity of these effects. When compared 
with reference clodronate formulations not con-
taining lidocaine,94 the i.m clodronate/lidocaine 
formulation showed significant reduction of pain 
intensity upon injection and for up to 2 hours af-
terwards. With regard to the newly tested dose 
regimens of i.m. clodronate, the administration 
of twice the drug dosage in a week significantly 
improved the efficacy of the treatment without 
inducing serious adverse events.34
Discussion
This review has examined the available literature 
on the use of clodronate in the treatment and pre-
vention of primary and secondary osteoporosis, 
and its potential role in other musculo-skeletal 
diseases.
a variety of clinical trials conducted over 
more than two decades have provided a strong 
level of evidence on the efficacy and safety of 
clodronic acid in the maintenance or improve-
ment of BMd and in reduction of risk of frac-
tures when given orally, i.m. or i.v. in patients 
with postmenopausal osteoporosis. clodronate 
was also used with success in the prevention or 
treatment of different forms of secondary osteo-
porosis, including GiOP and bone mass loss due 
to neoplastic or endocrine diseases.
Clodronate has shown interesting anti-inflam-
matory and analgesic properties that may lead to 
beneficial effects of the drug on pain and inflam-
mation. Studies in animal models highlighted 
a pain-relieving and antinociceptive effect of 
clodronate both at central and peripheral level 
that is independent from antifracture effect and 
is achieved at doses lower than those inducing 
anti-bone-resorptive effects.2 Furthermore, it has 
been shown that clodronate reduces the pain in 
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regimen with 200 mg i.m. clodronate improves 
adherence with the same clinical efficacy (in 
terms of BMD increase) and side-effect profile 
as weekly administration of 100 mg.32, 33
With regards to the newly tested indications, 
further clinical studies involving larger cohorts 
are needed to optimize the dosage and length of 
therapy of clodronate in each clinical field in or-
der to be able to maximize its properties on mod-
ulation of inflammation and bone remodeling. As 
an example, it is likely that the negative results on 
bone mass observed in one study in patients with 
thalassemia55 may be due to the low administered 
dose of clodronate (300 mg i.v. every 3 weeks).
The recommended dose regimen of clodronate 
in the approved indications is well established in 
the Summary of Product characteristics and in 
the information for prescription of the product. 
The proposed treatment regimens of clodronate 
in non-approved indications are summarized in 
Table VI and mainly reflect the experience of 
clinical trials. However, the dosage schemes test-
ed in the available clinical trials might have led 
to suboptimal results and further trials are nec-
essary for the definition of the most appropriate 
dosage of clodronate in each of the non-approved 
indication. as an example, the dose of i.v. clodro-
nate used in the treatment of CRPS (i.e. a global 
dose of 3000 mg given in 10 days) although ef-
fective, seem to be inadequate to maximise clini-
cal response. With the availability of the 200 mg 
i.m. formulation, a dose of 200 mg for 10 days 
and then 200 mg every other days for 20 days 
i.e. a cumulative dose of 4 g in a month (with 
a range of i.m. formulations of clodronate 
(without local anesthetic or with lidocaine) are 
currently approved in italy. The availability of 
an i.m. formulation not requiring infusion over 
limited time frames, while allowing at the same 
time an intermittent administration, overcomes 
the limitations of the long-term daily treatment 
with the oral form, and hence the risk of gastroin-
testinal adverse effects. The intermittent admin-
istration offers important advantages compared 
with daily oral administration, resulting in po-
tential improvement in compliance, and counter-
acts the problem of low bioavailability, further 
exacerbated by the intake of food and bever-
ages.97 importantly, clodronate and other BPs 
are characterized by a direct correlation between 
dose and densitometric effect.98 as it is widely 
accepted that a reduction in the dosing frequency 
of BPs may improve adherence and therefore 
therapeutic outcomes,99 an increase in the inter-
val between consecutive administrations should 
be associated with a concomitant increase in the 
overall BPs dose received.
Studies show that the two formulations of clo-
dronate now used in osteoporosis (i.m. and oral) 
are associated with similar increases in BMd, 
with slightly higher values for the i.m. formula-
tion.16 Moreover, the i.m. formulation appears to 
be more effective than intermittent i.v. treatment.24
With regard to dose schedule, it has been 
suggested that the optimal interval between 2 
consecutive administrations of i.m. clodronic 
acid may be 15-20 days, i.e. the time span of 
osteoclast activation.21, 35 The “twice-a-month” 
Table VI.—Proposed treatment regimens of clodronate in non-approved indications.
indication Proposed treatment regimen
Bone marrow edema syndromes (CPRS-I) 200 mg i.m. for 10 days and then 200 mg i,m, every other days for 20 days i.e. a 
cumulative dose of 4 g in a month (with possible repeated schemes in particular 
cases)
Osteoarthritis 300 mg i.v. for 7 days, followed by 100 mg/day i.m. for 14 days every 3 months;
or
2 mg i.a. weekly for 4 weeks
Orthopedic surgery 1600 mg/day oral from 3 weeks before to 6 months after surgery;
or
1800 mg i.v. postoperatively in two consecutive days and then 900 mg i.v. every 
two months after surgery)
or
100 mg/day i.m. in the first week, then every week for 6 months and then every 2 
weeks for the next 6 months
crPS-i: complex regional pain syndrome type i; i.v.: intravenous; i.m.: intramuscular; i.a.: intra-articular.
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